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Abstract: The development of a new one-pot sequential cyclizations involving a Vilsmeier-Haack 
reaction followed by an organocatalyzed Mannich reaction is reported. This synthetic strategy gives 
access to functionalized indolizidines and quinolizidines in one operation from readily synthesized 
precursors. Yields and diastereoselectivities are good to excellent when formamides are used to trigger 
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the key step, bearing either an electron-rich aryl or a pyrrole as the nucleophilic partner in the first 
cyclization. 
Introduction 
Substituted indolizidines and quinolizidines are attractive molecular scaffold because of their high 
occurrence in natural products exhibiting notable biological activity, as represented by the Erythrina 
family (erythraline shown), (+)-oleracein E, (+)-harmicine, (–)-tangutorine, and vincamine (Figure 1).1 
These scaffolds could also be found in several drugs developed by the pharmaceutical industry. 
 
 
Figure 1. Representative indolizidine, quinolizidine, and cyclohexapiperazine alkaloids and drugs. 
 
In our previous work, we reported an original approach with two consecutive nucleophilic cyclizations 
onto an activated amide 1 to access quinolizidines 3 (Scheme 1).2 The originality of such an approach 
resides in its complementarity with reported double cyclization strategies usually involving C-N bond 
formation.3 However, one of the limitations of our initial approach is the second cyclisation (Mannich), 
suffering from reactivity issues. Indeed, the conjugated iminium intermediate 2 could be trapped only 
with an allylsilane, an allylstannane, or an indole as the nucleophile. The use of a stronger nucleophile, 
such as an enol ether or an enamine 4, is not possible because that nucleophile reacts in the first 
cyclization, leading to a conjugated iminium intermediate 5/6 that is essentially not reactive for the last 
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cyclization step. Another limitation to this initial work is the poor functionalization of the final 
quinolizidine 3, substituted with only alkenes that would need to be differentiated in order to further 
transform this scaffold into natural products or drugs. Although strategies to increase the reactivity of the 
iminium ion for the Mannich cyclization were envisaged, a simpler solution is to rather increase the 
reactivity of the nucleophile. To do so, we need to run the Vilsmeier-Haack cyclization in the presence of 
a latent nucleophile that would be unveiled after the Vilsmeier-Haack cyclization. One of the best carbon 
-nucleophile we thought would fit this requirement is an enamine, prepared in situ from the 
corresponding aldehyde or ketone 8. This way, we expect to be able to widen the range of accessible 
molecular scaffolds containing indolizidines and quinolizidines 9, with suitable strategic functionalization 
for synthetic applications. 
 
Scheme 1. Targeted transformation. 
 
 
Although organocatalyzed Mannich reactions have been extensively studied,4,5 using such a reaction in 
a one-pot sequential process presents significant challenges. Firstly, the amide activation for the 
Vilsmeier-Haack cyclization needs to be performed chemoselectively in the presence of a ketone or an 
aldehyde 7.6 Secondly, the iminium intermediate 8 has to be stable enough in solution so that a complete 
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Vilsmeier-Haack cyclization occurs before the addition of amine to launch the intramolecular Mannich 
reaction. Thirdly, water generated during the amine condensation with the aldehyde or ketone 8 should 
not hydrolyze the remaining iminium intermediate 8. Fourthly, the amine added for enamine formation 
must not react with iminium intermediate 8, or at least not irreversibly. Lastly, enamine regioisomers 
resulting from amine condensation with the ketone 8 should reversibly interconvert so that ring size in the 
organocatalyzed Mannich cyclization could be controlled. 
 
Results and Discussion 
We started our investigation by testing the reaction cascade on substrates bearing an aldehyde. 
Substrates 16a and 16b were prepared according to the route detailed in Scheme 2. Quantitative reduction 
of 2,2-dimethylglutaric acid (10) followed by monoprotection and Swern oxidation afforded aldehyde 
12b.7 Aldehydes 12a8 and 12b were then independently subjected to three consecutive steps performed 
one-pot, starting with a condensation with amine 13 followed by reduction of the corresponding imine 
and formylation with N-formylbenzotriazole (N-(CHO)Bt). After deprotection of silyl ethers 14a,b, a 




Scheme 2. Synthesis of aldehydes 16a,b. 
 
 
Upon treatment of substrate 16a with triflic anhydride, we were pleased to see a complete amide 
activation and trapping of the resulting triflyliminium ion with the aryle to generate the iminium ion 
intermediate 17a with satisfactory preservation of the aldehyde group (Table 1). To the best of our 
knowledge, this is the first report of a chemoselective amide activation and nucleophilic trapping in the 
presence of an aldehyde.6 This Vilsmeier-Haack cyclization was performed at low temperature (–64 to –
15 °C) over a period of one hour. Three equivalents of piperidine were added and quinolizidine 18a was 
obtained in 30% yield as a single trans-diastereomer (entry 1). To ensure that the Mannich cyclization 
was catalyzed by piperidine, the non-catalyzed background reaction was tested (no piperidine added) and 
no quinolizidine was observed (entry 2). To discard any catalytic effect of piperidine due to simple 
enolization of the aldehyde rather than formation of an enamine, the reaction was tested in acidic (CSA, 
entry 3) or basic (Et3N, entry 4) conditions. Again, no conversion occurred. Temperature proved to be 
critical: increasing temperature from –15 °C to rt or to 70 °C resulted in a dramatic yield loss (entries 5, 
1, and 6, respectively). To better understand this observation, we activated amide 16a without treating 
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with piperidine afterward, and proved by 1H NMR that iminium ion 17a decomposed at 0 °C in less than 
30 min. 
 











1 16a Piperidine (3) 3 d rt 18a (30%) > 19:1 
2 16a None 3 d rt 0  
3 16a CSA (5) 3 d rt 0  
4 16a Et3N (3) 3 d rt 0  
5 16a Piperidine (3) 3 d –15 40  
6 16a Piperidine (3) 3 d 70 18a (< 20%) > 19:1 
7 16a Piperidine (15)b 3 d –15 18a (52%) > 19:1 
8 16a Pyrrolidine (3) 18 h –15 18a (45%) > 19:1 




aReaction conditions for the Vilsmeier-Haack cyclization (16 to 17): i- Tf2O (1.1 equiv.), 
DTBMP (1.1equiv.), CDCl3 (0.05 M), –64 °C to –15 °C, 1 h. bThe reaction mixture was 
diluted to 0.003 M with CDCl3. cYield based on recovered starting material 16b. 
dDiastereomeric ratio determined by 1H NMR analysis of crude material. 
 
Besides the poor stability of iminium intermediate 17a, we thought two other factors could impede the 
overall conversion. One is a competition between intra- and intermolecular addition of the transient 
piperidine enamine of aldehyde 17a. Hence, to favor intramolecular attack of the enamine, dilution of the 
reaction medium before addition of piperidine was operated and, interestingly, the yield improved 
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significantly, now up to 52% (entry 7). The second factor is a possible competitive addition of piperidine 
onto the iminium portion of intermediate 17a rather than on the aldehyde. If the addition on the iminium 
ion occurs and is poorly reversible, the final Mannich cyclization would be hampered and intermediate 
17a (or its piperidine adduct) would decompose over time. To verify this last hypothesis, a model substrate 
lacking the aldehyde portion was synthesized (Scheme 3). Substrate 20 was prepared from amine 13 in 
two almost quantitative steps. Upon activation, amide 20 was trapped with the aryl group. Piperidine was 
then added to the resulting iminium ion 21. After six days at room temperature, analysis of the 1H NMR 
spectrum showed that integrity of iminium ion 21 was preserved, without any observable addition of 
piperidine to form ammonium 22a and/or 22b. This prove that addition of the secondary amine is either 
not occurring, or is reversible with a strong preference toward conjugated iminium ion 21 over ammonium 
ions 22a,b. It should be noted that the observed stability of iminium 21 over six days at rt is a strong 
indication that the low stability of iminium ion 17a is due to the aldehyde portion of the molecule. 
Switching to pyrrolidine (Table 1, entry 8) accelerated the overall process, and the yield was slightly 
better than with piperidine (entry 5). To increase the yield, it seemed that the possible options were to 
accelerate the organocatalyzed Mannich reaction or to improve the stability of the iminium intermediate. 
To accelerate the Mannich reaction, we opted for a Thorpe-Ingold effect by adding a gem-dimethyl group 
on the alkyl chain containing the aldehyde, combined to a reduction of reaction time to limit a possible 
degradation of iminium intermediate 17b. The anticipated acceleration did not materialize: roughly the 
same yield was obtained with substrates 16b (37%, entry 9) and 16a (40%, entry 5), with an incomplete 




Scheme 3. Possible piperidine addition to iminium intermediate. 
 
To improve the stability of the iminium intermediate, we decided to switch to ketones instead of 
aldehydes. Therefore, keto-amide 28a was prepared following the synthetic sequence presented in 
Scheme 4. The synthesis started with the quantitative opening of lactone 23 with amine 13 using AlMe3, 
followed by reduction of the resulting amide 24 to amino alcohol 25. Attempts to perform a selective 
formylation of the amine gave mixtures of monoformylated product 27 and N,O-diformylated congener 
26. We thus decided to perform an extensive formylation to 26 followed by a selective formate 
methanolysis to successfully afford alcohol 27 in 73% yield over the last three steps. A Swern oxidation 




Scheme 4. Synthesis of ketone 28a. 
 
 
After activation of amide 28a in the usual conditions, we were pleased to observe that iminium 
intermediate 29 was much more stable than its aldehyde analogue 17a or 17b; the Vilsmeier-Haack 
reaction could now be run at 0 °C for only 5 min, and the integrity of iminium intermediate 29 is preserved 
at room temperature over at least 18 h (proven by 1H NMR). Preliminary tests with substrate 28a using 
three equivalents of pyrrolidine or piperidine afforded the desired compound 30a as a single diastereomer 
in good yields (Table 2, entries 1 and 2, respectively), with pyrrolidine being the best catalyst for the 




Table 2. Screening of amines.a 
 
Entry Additive Yield (%) 
1 Pyrrolidine 73 
2 Piperidine 44 
3 None 0 
4 CSA 0 
5 Et3N 0 
6 Morpholine 51 
7 Et2NH 48 
8 Cyclohexylamine 45 
9 
Pyrrolidine (0.5 equiv.) 
+ DIPEA (2 equiv.) 
55 
a Reaction conditions: i- Tf2O (1.1 equiv.), 
DTBMP (1.1equiv.), CDCl3 (0.05 M), 0 °C, 5 
min; ii- additive (3 equiv.), rt, 18 h. 
 
Because the condensation of an amine with a ketone may present different kinetics than with an 
aldehyde, it was necessary to rule out the uncatalyzed Mannich reaction with this ketone substrate as well. 
Hence, we proved that the secondary amine was necessary for the second cyclisation (entry 3) and that 
acid or base-promoted enolization of the ketone (and subsequent Mannich) is not operating (entries 4 and 
5, respectively). Other secondary (morpholine and diethylamine, entries 6 and 7, respectively) or primary 
(cyclohexylamine, entry 8) amines all furnished bicyclic product 30a in similar yields. The amount of 
needed secondary amine catalyst was determined by 1H NMR experiment. After amide activation and 
Vilsmeier-Haack cyclization, there is one equivalent of 2,6-di-tert-butyl-4-methylpyridinium triflate 
 12 
(DTBMP•HOTf) generated. Because the secondary amines tested are more basic than DTBMP, three 
equivalents of secondary amine were necessary to observe one equivalent of basic amine in solution.11 
Lower amounts of secondary amine (down to 0.5 equiv. of pyrrolidine) still catalyze the reaction, but a 
tertiary amine (2 equiv. of DIPEA) is usually needed to ensure enough non protonated secondary amine 
is present in solution (entry 9). Higher amounts of secondary amine (up to 35 equivalents) accelerate the 
reaction, but ruins any 1H NMR analysis of the progression of the reaction. 
 
When we get a closer look at the major diastereomers of quinolizidines 18a and 30a (Figure 2), in the 
aldehyde and ketone series, respectively, we notice an intriguing opposite diastereomeric relation. We 
explain this difference with a model presented in Scheme 5. The Mannich cyclization of aldehyde enamine 
31 or ketone enamine 32 should process through the least hindered transition state TS1 also presenting 
the lowest global dipole. Therefore, the direct diastereomeric product of cyclization should be cis and 
presents an equatorially oriented carbonyl substituent. However, the less congested axially oriented 
carbonyl in the trans isomer should be thermodynamically favored, now allowing a trans ring junction in 
the quinolizidine portion of the molecule (c.f. X-ray structures of 18a and 30a, Figure 2).12,13 
Epimerization to the axial carbonyl group necessitates enolization, either to the corresponding enamine 
(34, X = pyrrole) or ketone (34, X = O). Such enolization is not likely in the ketone series, presenting 
severe steric interactions in 34 (R = Me) and this may account for the observed trans isomer in the 





Figure 2. X-ray structures of quinolizidines 18a and 30a.12 
 
Scheme 5. Mechanistic proposition for diastereoselectivities observed in 18a and 30a. 
 
 
The scope of the reaction was studied with a series of veratrole substrates bearing a formamide or 
acetamide, linked to a ketone with different tether length. Those substrates (28b-f, depicted in Table 3) 
were synthesized following the strategy described in Scheme 4, starting with lactones of different ring 
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sizes. We also investigated heteroaromatic nucleophiles for the initial Vilsmeier-Haack cyclization. 
Pyrrole substrates 41a-c were synthesized according to the route described in Scheme 6. Iodoethylpyrrole 
37 was obtained from condensation of commercially available 2,5-dimethoxytetrahydrofuran (35) and 2-
aminoethanol followed by iodination.14 Amines 38a,b were then alkylated with iodide 37 and the 
corresponding amino alcohol were bis-formylated then selectively methanolyzed. The resulting amido 
alcohols were oxidized using Dess-Martin periodinane to afford the desired compound 39a-c. 
 
Scheme 6. Preparation of pyrrole substrates. 
 
 
Finally, indole substrates were also prepared. 3-Substituted N-methylindoles 44a,b (depicted in Table 
3) were obtained from 1-methyltryptamine following the strategy described in Scheme 4, whereas 
compound 44c necessitated a different approach (Scheme 7). The ketone chain was prepared from alcohol 
40.15 Iodination and N-alkylation with the anion of indole 4216 afforded dioxolane 43, which was 
hydrolyzed to the desired ketone 44c. 
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Scheme 7. Preparation of indole substrates. 
 
 
The Vilsmeier-Haack cyclization is endo-exo according to Ben-Ishai nomenclature for sp2 nucleophiles 
reacting with sp2 electrophiles.17 Hence, the electrophilic triflyliminium ion resulting from amide 
activation is endocyclic with respect to the ring in formation, and the nucleophile is exocyclic for all 
substrates of Table 3, except for 28f, which presents an endo-endo cyclization mode.18 The Vilsmeier-
Haack cyclization was run at –15 °C over one hour for aldehyde substrates 16a,b, whereas higher 
temperature (0 °C) and shorter time (5 min) were sufficient for ketones substrates when formamides (28a, 
28b, 28e, 28f,39-c, and 446a-c) were activated. In cases of activation of acetamides (28c and 28d), the 
Vilsmeier-Haack cyclization necessitated prolonged reaction time (4 h) at room temperature. The 
Mannich cyclization catalyzed by piperidine gave higher yields with aldehydes 16a,b, but in general, 
pyrrolidine was the best catalyst. In all cases, the secondary amine for the organocatalyzed Mannich 
cyclization was used in excess (3-6 equivalents), and the best conditions are reported in Table 3. 




Table 3. Substate scope.a 
Entry Substrate Product12,13 Yield (%) d.r.j 
1b 
16a 18a  
















24h > 19:1 
6c 
28d 30d 
18 > 19:1 
7d 
28e 30e 
95 > 19:1 
8d 




87 > 19:1 
 17 
10 
39b 49b  






18 > 19:1 
13 
44b 
   







aReaction conditions: i- Tf2O (1.1 equiv.), DTBMP (1.1equiv.), CDCl3 (0.05 M), 0 °C, 5 min; ii- 
pyrrolidine (3 equiv.), rt, 18 h. bThe Vilsmeier-Haack cyclization was run at –15° C for 45-60 min. 
cThe Vilsmeier-Haack cyclization was run at rt for 4 h. dReaction run in DCM. eReaction medium 
was diluted with CDCl3 to 0.003 M prior to the addition of piperidine (15 equiv.). The Mannich 
cyclization was run at –15 C for 3 d. With pyrrolidine (3 equiv.), 45% yield was obtained. 
fPiperidine (3 equiv.) was used for the Mannich cyclization at –15 C for 18 h. gWith piperidine (3 
equiv.), 44% yield was obtained. h6 equiv. of pyrrolidine were used. i1.5 equiv. of pyrrolidine was 
used. jDiastereomeric ratio determined by 1H NMR analysis of crude material. kMajor diastereomer 
not assigned. 
 
As for aldehydes 16a,b (entries 1 and 2), the gem-dimethyl had essentially no effect on the rate and 
yield for the Mannich cyclization of ketone substrates 28a,b (entries 3 and 4, respectively). For ketone 
28a, we obtained 73% overall yield for the double cyclizations using pyrrolidine in the organocatalyzed 
Mannich reaction, whereas only 44% yield was obtained when using piperidine. From here, all other 
substrates were treated with pyrrolidine only. 
 
Formation of a quaternary center at ring junction from the activation of acetamides 28c and 28d 
compared to their formamide congeners 28a and 28b, respectively, revealed to be challenging, as expected 
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(entries 3-6). Here too, no Thorpe-Ingold acceleration was observed with the gem-dimethylated substrates 
28b (c.f entries 3 vs 4) or 28d (c.f entries 5 vs 6). 
 
Formation of a 5-membered ring in the Mannich cyclization was much more efficient (c.f. entries 3 vs 
7), with a nearly quantitative overall yield for indolizidine 30e. It should be noted that in cases depicted 
in entries 3-7, condensation of the secondary amine with the ketone results in the most substituted, 
thermodynamically favored enamine for the Mannich cyclization. However, in entry 8, the enamine needs 
to be formed in the terminal position (see 46, Scheme 8). If enamines 46 and 47equilibrate rapidly, low 
concentration of terminal enamine 46 is expected, thus slowing the Mannich reaction. Hence, side reaction 
may take place, such as intermolecular addition of thermodynamic enamine 47 onto iminium ion or retro 
aza-Michael reaction leading to fragmented product 48, which might account for the low yield observed 
for quinolizidine 30f (Table 3, entry 8). 
 




For substrates bearing a pyrrole instead of a veratrole unit as the nucleophilic partner in the Vilsmeier-
Haack cyclization, we observed comparable good to excellent yields for the formation of indolizidines 
(cf. 30e, entry 7, and49, entry 9) and quinolizidines (cf. 30a, entry 3, and 49b, entry 10). For pyrrole 
substrate 49c (entry 11) as for veratrole substrate 28c (entry 5), formation of quaternary center at ring 
junction from activation of an acetamides proved to be difficult. 
 
When indole is used as the initial nucleophile in the Vilsmeier-Haack cyclization, the ensuing 
organocatalyzed Mannich reaction is much less efficient (see substrates 44a-c, entries 12-14). A greater 
steric hindrance around the iminium intermediate 53 generated by the N-substituted indole ring likely 
accounts for the low overall yield, when compared to veratrole 51 or pyrrole 52 analogues (Figure 3). 
 
 
Figure 3. Congestion around iminium ion intermediates 51, 52, and 53. 
 
Conclusion 
In conclusion, we successfully developed a new one-pot reaction sequence involving a Vilsmeier-Haack 
cyclization followed by an organocatalyzed Mannich cyclization as a rapid access to benzo- and pyrrolo-
indolizidines and quinolizidines. The Vilsmeier-Haack first cyclization is compatible with electron-rich 
aryl and pyrrole nucleophiles, as well as with free ketones and even free aldehydes, to a certain extent. 
Higher yields were obtained when formamides were reacted compared to their acetamide congeners. The 
iminium intermediate resulting from Vilsmeier-Haack cyclization does not interfere with the enamine 
formation necessary for the organocatalyzed Mannich cyclization. The latter gave generally higher yields 
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when pyrrolidine was used as the secondary amine, and proved to be much more efficient in this 
organocatalyzed variant than in our initially reported allylsilane version. Precursors to the key double 
cyclizations are easily accessible, and the key transformation gives high diastereoselectivities. This new 
synthetic strategy is suitable for the preparation of libraries of functionalized indolizidines and 
quinolizidines as privileged structures to explore new chemical spaces in medicinal chemistry programs. 
 
Experimental Section 
General Information. All reactions requiring anhydrous conditions were conducted in flame-dried 
glassware under a dry nitrogen or argon atmosphere. Compounds lacking experimental details were 
prepared according to the literature as cited and are in agreement with published spectra. THF was distilled 
from Na and benzophenone at atmospheric pressure. DCM, toluene, diisopropylethylamine, triethylamine 
and pyrrolidine were distilled from CaH2 at atmospheric pressure. Triflic anhydride (Tf2O), TFAA and 
chlorobenzene were distilled over a small amount of P2O5 at atmospheric pressure prior to use. Methanol 
was distilled over 4 Å molecular sieves at atmospheric pressure. 2,6-di-tert-Butyl-4-methylpyridine 
(DTBMP) was synthesized following the reported procedure in literature.19 All other required fine 
chemicals were used directly without purification. Thin layer chromatography (TLC) was conducted with 
pre-coated 60 Å 250 m silica gel plates with F-254 indicator and visualized using a combination of UV 
and anisaldehyde, ceric ammonium molybdate, iodine on silica, or potassium permanganate staining. 
Flash column chromatography was performed using silica gel (230–400 mesh). IR spectra were recorded 
with a FTIR instrument by applying substrates as thin films. 1H and proton-decoupled 13C NMR spectra 
were recorded on 300 MHz and/or 400 MHz spectrometers. All chemical shifts are referenced to residual 
non-deuterated solvent. 1H NMR coupling constants are reported in Hertz and refer to apparent 
multiplicities and not true coupling constants. Data for proton spectra are reported as follows: chemical 
shift (multiplicity [singlet (s), doublet (d), triplet (t), quartet (q), quintet (quint), and multiplet (m)], 
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integration, coupling constants [Hz]). Carbon spectra were recorded with complete proton decoupling and 
the chemical shifts are reported in ppm. Mass spectra were recorded with an ESI-Q-TOF instrument. 
Usual Reaction Workup and Purification. After addition of the indicated aqueous solution, layers 
were separated. The aqueous phase was extracted with the indicated solvent, and the combined organic 
phases were washed with the indicated aqueous solution (if needed), dried over anhydrous MgSO4, filtered, 
and concentrated under reduced pressure using a rotary evaporator. The crude material was purified by 
flash chromatography using silica gel with the indicated eluent. 
2,2-Dimethylpentane-1,5-diol (11). A solution of 2,2-dimethylglutaric acid (10, 5.0 g, 31.2 mmol) in 
Et2O (12.0 mL) was added dropwise to a solution of LiAlH4 (4.0 g, 106 mmol) in Et2O (170 mL) at 0 °C 
and the mixture was refluxed for 18 h. The resulting mixture was cooled at 0 °C and quenched with water 
(4.0 mL). An aqueous solution of NaOH (15%, 4.0 mL) and water (12.0 mL) were added, and the mixture 
was stirred vigorously at rt for 3 h. Anhydrous Na2SO4 was added and the mixture was stirred for 15 min, 
filtered over Celite and concentrated under reduced pressure to afford 11 as a colorless oil (4.21 g, 99%). 
The residue was used directly in the next step. 1H NMR (300 MHz, CDCl3) δ (ppm) 3.64 (t, J = 6.3 Hz, 
2H), 3.33 (s, 2H), 1.75 (br s, 2H), 1.59 – 1.49 (m, 2H), 1.34 – 1.28 (m, 2H), 0.88 (s, 6H). 13C{1H} NMR 
(75 MHz, CDCl3) δ (ppm) 71.0 (t), 63.3 (t), 34.9 (s), 34.3 (t), 26.9 (t), 24.3 (q). IR (neat) ν (cm-1) 3318 
(br), 2943, 2869. HRMS (positive ESI) Calcd for C7H16O2Na [MNa+]: 155.1043, found 155.1044. 
2,2-Dimethyl-5-((triisopropylsilyl)oxy)pentanal (12b). A solution of crude 11 (9.54 g, 72.2 mmol) in 
THF (38 mL) was added dropwise over 20 min to a suspension of NaH (60% dispersion in mineral oil, 
5.77 g, 144 mmol) in THF (150 mL) at 0 °C. The mixture was stirred for 30 min at rt then cooled to 0 °C. 
A solution of TIPSCl (15.6 mL g, 72.8 mmol) in THF (12 mL) was added dropwise and the solution was 
stirred at 0 °C for 40 min. Water was added and the usual work-up (Et2O) and purification (2 to 6% EtOAc 
in hexanes) afforded 2,2-dimethyl-5-((triisopropylsilyl)oxy)pentan-1-ol (17.5 g, 84%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) δ (ppm) 3.69 (t, J = 6.5 Hz, 2H), 3.35 (d, J = 6.0 Hz, 2H), 1.59 – 1.48 (m, 
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3H), 1.34 – 1.29 (m, 2H), 1.09 (s, 21H), 0.90 (s, 6H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 71.8 (t), 
64.3 (t), 35.0 (s), 34.5 (t), 27.5 (t), 24.1(q), 18.1 (q), 12.1 (d). IR (neat) ν (cm-1) 3345 (br), 2942, 2891, 
2865. HRMS (positive ESI) Calcd for C16H36O2SiNa [MNa+]: 311.2377, found 311.2385. DMSO 
(5.0 mL, 70.3 mmol) was added to a solution of oxalyl chloride (3.43 mL, 40.6 mmol) in DCM (200 mL) 
at -78 °C. The reaction mixture was stirred for 30 min at -78 °C then a solution of 2,2-dimethyl-5-
((triisopropylsilyl)oxy)pentan-1-ol (7.80 g, 27.0 mmol) in DCM (135 mL) was added. Stirring was 
continued for 1 h at -78 °C then triethylamine (18.7 mL, 135 mmol) was added. The solution was stirred 
for 1 h at -78 °C then allowed to warm up to rt over 3 h. Water was added and the usual work-up (DCM) 
and purification (2% EtOAc in hexanes) afforded 12b (6.84 g, 88%) as a colorless oil. 1H NMR 
(300 MHz, CDCl3) δ (ppm) 9.43 (s, 1H), 3.64 (t, J = 6.0 Hz, 2H), 1.56 – 1.38 (m, 4H), 1.03 (s, 27H). 
13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 206.3 (d), 63.5 (t), 45.6 (s), 33.5 (t), 27.9 (t), 21.4 (q), 18.1(q), 
12.1 (d). IR (neat) ν (cm-1) 2959, 2944, 2886, 1724. HRMS (positive ESI) Calcd for C16H34O2SiNa 
[MNa+]: 309.2220, found 309.2222. 
N-(5-((tert-Butyldimethylsilyl)oxy)pentyl)-N-(3,4-dimethoxyphenethyl)formamide (14a). 2-(3,4-
Dimethoxyphenyl)ethylamine (0.91 mL, 5.41 mmol) was added to a solution of 5-((tert-
butyldimethylsilyl)oxy)pentanal20(1.17 g, 5.41 mmol) in DCM (11 mL) at rt. The solution was stirred for 
1 h at rt then anhydrous MgSO4 (1.30 g, 10.8 mmol) was added. The mixture was stirred for 1 h at rt then 
filtered and washed with DCM (25 mL). MeOH (15 mL) and sodium borohydride (303 mg, 10.8 mmol) 
were added. The solution was stirred for 18 h at rt. Water (15 mL) was added and the usual work-up 
(DCM, brine) afforded a residue that was used directly in the next step. N-Formylbenzotriazole (1.06 g, 
6.49 mmol) was added to the residue dissolved in THF (27 mL). The solution was stirred for 18 h at rt 
then the solvent was removed under reduced pressure. The residue was dissolved in DCM and washed 
with aqueous NaOH (2 M, 2 × 25 mL). The usual work-up (DCM) and purification (20 to 55% EtOAc in 
hexanes) afforded 14a (247 mg, 84%) as a colorless oil. 1H NMR (300 MHz, CDCl3) 1:0.8 mixture of 
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rotamers δ (ppm) 8.05 (s) and 7.82 (s) (1H, rotamers), 6.81 – 6.74 (m, 2H), 6.69 – 6.62 (m, 1H), 3.87 (s) 
and 3.86 (s) (3H, rotamers), 3.62 – 3.57 (m, 2H), 3.52 – 3.47 (m, 2H), 3.41 (t, J = 7.0 Hz, 1H, rotamers), 
3.35 – 3.30 (m, 1H), 3.11 (t, J = 7.0 Hz, 1H, rotamers), 2.82 – 2.73 (m, 2H), 1.63 – 1.46 (m, 4H), 1.39 – 
1.25 (m, 2H), 0.89 (s) and 0.88 (s) (9H, rotamers), 0.04 (s) and 0.03 (s) (6H, rotamers). 13C{1H} NMR 
(75 MHz, CDCl3) mixture of rotamers δ (ppm) 162.7, 162.6, 149.0, 148.9, 147.8, 147.6, 131.3, 130.3, 
120.8, 120.6, 111.9, 111.4, 111.2, 62.9, 62.7, 55.85, 55.82, 49.1, 47.9, 44.2, 42.3, 35.0, 33.2, 32.4, 32.2, 
28.5, 27.2, 25.92, 25.89, 23.2, 22.8, 18.28, 18.26, -5.33, -5.35. IR (neat) ν (cm-1) 2930, 2855, 1669, 1515, 
1463, 1258, 1236. HRMS (positive ESI) Calcd for C22H39NO4Si [MNa+]: 432.2541, found 432.2540. 
N-(3,4-Dimethoxyphenethyl)-N-(2,2-dimethyl-5-((triisopropylsilyl)oxy)pentyl)formamide (14b). 
Following the procedure used to prepare 14a, 12b (2.22 g, 7.76 mmol) was treated with 2-(3,4-
dimethoxyphenyl)ethylamine (1.30 mL, 7.76 mmol) in DCM (15 mL), then with sodium borohydride 
(0.56 g, 15.5 mmol) in MeOH (20 mL). After the usual work-up (DCM, brine), the residue was treated 
with N-formylbenzotriazole (1.37 g, 9.31 mmol) in THF (40 mL) then with NaOH (2 M). The usual work-
up (DCM) and purification (20 to 40% EtOAc in hexanes) afforded 14b (3.7 g, 98%) as a colorless oil. 
1H NMR (300 MHz, CDCl3) 1: 0.5 mixture of rotamers δ (ppm) 8.02 (s) and 7.88 (s) (1H, rotamers), 6.78 
(d, J = 8.5 Hz, 1H), 6.73 – 6.59 (m, 2H), 3.86 (s) and 3.84 (s) (6H, rotamers), 3.66 – 3.47 (m, 4H), 3.14 
(s) and 2.88 (s) (2H, rotamers), 2.81 – 2.71 (m, 2H), 1.59 – 1.43 (m, 2H), 1.31 – 1.19 (m, 2H), 1.04 (s, 
21H), 0.90 (s) and 0.85 (s) (6H, rotamers). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ (ppm) 
163.8 (d), 163.6 (d), 149.0 (s), 148.8 (s), 147.8 (s), 147.5 (s), 131.3 (s), 130.1 (s), 120.8 (d), 120.6 (d), 
111.9 (d), 111.3 (d), 111.2 (d), 63.8 (t), 63.5 (t), 58.1 (t), 55.7 (q), 51.6 (t), 51.0 (t), 47.6 (t), 36.8 (t), 
36.1(s), 36.0 (t), 35.3 (s), 34.9 (t), 33.0 (t), 27.5 (t) 27.3 (t), 25.8 (q) 25.1 (q), 17.9 (q), 11.8 (d). IR (neat) 
ν (cm-1) 2942, 2892, 2864, 2046, 1673. HRMS (positive ESI) Calcd for C27H49NO4SiNa [MNa+]: 
502.3323, found 502.3325. 
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N-(3,4-Dimethoxyphenethyl)-N-(5-hydroxypentyl)formamide (15a). A solution of TBAF (1.0 M in 
THF , 2.84 mL, 2.84 mmol) was added dropwise to a solution of 14a (972 mg, 2.37 mmol) and glacial 
acetic acid (0.27 mL, 4.74 mmol) in THF (12 mL). The solution was stirred for 18 h at rt then the solvent 
was removed under reduced pressure. Usual purification (70 to 100% EtOAc in hexanes then 5% MeOH 
in DCM) afforded 15a (631 mg, 90%) as a light brown oil. 1H NMR (300 MHz, CDCl3) 1:0.9 mixture of 
rotamers δ (ppm) 8.01 (s) and 7.78 (s) (1H, rotamers), 6.78 – 6.71 (m, 2H), 6.65 – 6.60 (m, 1H), 3.84 (s) 
and 3.83 (s) (3H, rotamers), 3.82 (s, 3H), 3.61 – 3.56 (m, 2H), 3.49 – 3.44 (m, 1H), 3.39 (t, J = 7.0 Hz, 
1H, rotamers), 3.32 – 3.27 (m, 1H), 3.09 (t, J = 7.0 Hz, 1H, rotamers), 2.79 – 2.70 (m, 2H), 2.30 (br s, 
1H), 1.61 – 1.45 (m, 4H), 1.39 – 1.22 (m, 2H). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ 
(ppm) 162.8 (d), 162.7 (d), 148.9 (s), 148.7 (s), 147.7 (s), 147.4 (s), 131.1 (s), 130.1 (s), 120.7 (d), 120.5 
(d), 111.81 (d), 111.78 (d), 111.3 (d), 111.1 (d), 62.1 (t), 62.0 (t), 55.8 (q), 49.1 (t), 47.8 (t), 44.1 (t), 42.1 
(t), 34.8 (t), 33.1 (t), 32.1 (t), 32.0 (t), 28.3 (t), 27.0 (t), 22.9 (t), 22.6 (t). IR (neat) ν (cm-1) 3416 (br), 
2932, 2858, 2834, 1655, 1510, 1450, 1260, 1234. HRMS (positive ESI) Calcd for C16H25NO4Na [MNa+]: 
318.1676, found 318.1684. 
N-(3,4-Dimethoxyphenethyl)-N-(5-hydroxy-2,2-dimethylpentyl)formamide (15b). Following the 
procedure used to prepare 15a, 14b (6.54 g, 13.5 mmol) was treated with TBAF (1.0 M in THF, 4.70 mL, 
16.4 mmol) in THF (12 mL). The usual purification (80 to 100% EtOAc in hexanes then 1% MeOH in 
DCM) afforded 15b (3.74 g, 85%) as a white solid. 1H NMR (300 MHz, CDCl3) 1:0.6 mixture of 
rotamers δ (ppm) 8.03 (s) and 7.88 (s) (1H, rotamers), 6.79 (d, J = 8.5 Hz, 1H), 6.74 – 6.60 (m, 2H), 3.86 
(s) and 3.85 (s) (3H, rotamers), 3.84 (s, 3H), 3.60 (t, J = 6.5 Hz, 2H), 3.55 – 3.48 (m, 2H), 3.13 (s) and 
2.89 (s) (2H, rotamers), 2.82 – 2.72 (m, 2H), 1.83 (br s, 1H), 1.64 – 1.46 (m, 2H), 1.31 – 1.20 (m, 2H), 
0.92 (s) and 0.87 (s) (6H, rotamers). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ (ppm) 164.2 
(d), 149.3 (s), 149.1 (s), 148.1 (s), 147.8 (s), 131.5 (s), 130.3(s), 121.0 (d), 120.8 (d), 112.2 (d), 112.1 (d), 
111.6 (d), 111.4 (d), 63.3 (t), 58.5 (t), 56.07 (q), 56.04 (q), 56.03 (q), 56.01 (q), 51.6 (t), 51.5 (t), 48.0 (t), 
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36.4 (s), 36.3 (t), 36.2 (t), 35.6 (s), 35.3 (t), 33.3(t), 27.3 (t), 27.2 (t), 26.4 (q), 25.3(q). IR (neat) ν (cm-1) 
3404 (br), 2941, 2872, 2162, 1659. HRMS (positive ESI) Calcd for C18H30NO4 [MH+]: 324.2169, found 
324.2168. Mp 58 – 63 °C. 
N-(3,4-Dimethoxyphenethyl)-N-(5-oxopentyl)formamide (16a). DMSO (0.38 mL, 5.33 mmol) was 
added to a solution of oxalyl chloride (0.26 mL, 3.08 mmol) in DCM (12 mL) at -78 °C. The solution was 
stirred for 30 min at -78 °C then a solution of 15a (605 mg, 2.05 mmol) in DCM (8.0 mL) was added. The 
solution was stirred for 1 at -78 °C then triethylamine (1.44 mL, 10.3 mmol) was added. The solution was 
stirred for 1 at -78 °C then was allowed to warm up to rt over 45 min. Water was added and the usual 
work-up (DCM) and purification (60 to 100% EtOAc in hexanes) afforded 16a (622 mg, 87%) as a yellow 
oil. 1H NMR (300 MHz, CDCl3) 1:0.9 mixture of rotamers δ (ppm) 9.76 (s, 1H), 8.06 (s) and 7.84 (s) 
(1H, rotamers), 6.82 – 6.74 (m, 2H), 6.69 – 6.63 (m, 1H), 3.88 (s) and 3.87 (s) (3H, rotamers), 3.86 (s, 
3H), 3.50 (dd, J = 8.5, 7.0 Hz, 1H), 3.43 (t, J = 7.0 Hz, 1H), 3.34 (t, J = 7.0 Hz, 1H), 3.12 (t, J = 6.5 Hz, 
1H), 2.83 – 2.74 (m, 2H), 2.52 – 2.44 (m, 2H), 1.63 -1.54 (m, 4H). 13C{1H} NMR (75 MHz, CDCl3) 
mixture of rotamers δ (ppm) 201.9 (d), 201.4 (d), 162.7 (d), 162.6 (d), 149.0 (s), 148.9 (s), 147.8 (s), 147.6 
(s), 131.2 (s), 130.2 (s), 120.8 (d), 120.6 (d), 111.9 (d), 111.4 (d), 111.2 (d), 55.8 (q), 49.0 (t), 47.6 (t), 
44.2 (t), 43.2 (t), 43.1 (t), 41.7 (t), 34.9 (t), 33.1 (t), 28.0 (t), 26.7 (t), 19.1 (t), 18.8 (t). IR (neat) ν (cm-1) 
2936, 2835, 1718, 1661, 1514, 1260, 1234, 1025. HRMS (positive ESI) Calcd for C16H23NO4Na [MNa+]: 
316.1519, found 316.1529. 
N-(3,4-Dimethoxyphenethyl)-N-(2,2-dimethyl-5-oxopentyl)formamide (16b). Following the 
procedure used to prepare 16a, 15b (3.74 g, 11.6 mmol) was treated with DMSO (2.14 mL, 30.1 mmol), 
oxalyl chloride (1.47 mL, 17.4 mmol), and triethylamine (8.02 mL, 57.9 mmol) in DCM (87 mL). The 
usual work-up (DCM) and purification (80% EtOAc in hexanes) afforded 16b (2.96 g, 79%) as a yellow 
solid. 1H NMR (300 MHz, CDCl3) 1:0.8 mixture of rotamers δ (ppm) 9.68 (s) and 9.67 (s) (1H, rotamers), 
7.95 (s) and 7.79 (s) (1H, rotamers), 6.73 – 6.71 (m, 1H), 6.66 – 6.54 (m, 2H), 3.78 (s) and 3.77 (s) (3H, 
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rotamers), 3.76 (s) and 3.75 (s) (3H, rotamers), 3.50 – 3.41 (m, 2H), 3.05 (s) and 2.82 (s) (2H, rotamers), 
2.75 – 2.65 (m, 2H), 2.44 – 2.39 (m, 1H), 2.35 – 2.29 (m, 1H), 1.45 (dd, J = 16.0, 7.5 Hz, 2H), 0.84 (s) 
and 0.78 (s) (6H, rotamers). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ (ppm) 202.4 (d), 
201.4 (d), 163.8 (d), 149.0 (s), 148.8 (s), 147.8 (s), 147.5 (s), 131.2 (s), 130.0 (s), 120.8 (d), 120.6 (d), 
111.9 (d), 111.8 (d), 111.4 (d), 111.3 (d), 58.3 (t), 55.9 (q), 55.8 (q), 55.7 (q), 51.3 (t), 51.2 (t), 47.9 (t), 
39.0 (t), 38.7 (t), 35.9 (s), 35.2 (s), 34.9 (t), 33.0 (t), 31.7 (t), 31.4 (t), 25.8 (q), 24.6 (q). IR (neat) ν (cm-
1) 2958 and 2936 (br), 2871, 2835, 2160, 1719, 1663. HRMS (positive ESI) Calcd for C18H28NO4 [MH+]: 
322.2013, found 322.2011. Mp 62 - 67 °C. 
trans-9,10-Dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinoline-1-carbaldehyde 
(18a). Triflic anhydride (91 µL, 0.54 mmol) was added dropwise to a solution of 16a (137 mg, 0.47 mmol) 
and DTBMP (161 mg, 0.78 mmol) in CDCl3 (9.40 mL) at -60 °C. The reaction mixture was stirred for 
45 min at this temperature then at -15 °C for 1 h. 1H NMR analysis of a small sample of the reaction 
mixture revealed the presence of iminium ion 17a. 1H NMR (400 MHz, CDCl3) δ (ppm) 9.77 (s, 1H), 
9.23 (s, 1H), 7.50 (s, 1H), 6.84 (s, 1H), 4.04 (t, J = 7.3 Hz, 2H), 4.01 (s, 3H), 3.96 (t, J = 8.2 Hz, 2H), 3.92 
(s, 3H), 3.23 (t, J = 8.2 Hz, 2H), 2.63 (t, J = 6.7 Hz, 2H), 1.95-1.88 (m, 2H), 1.73-1.64 (m, 2H). Piperidine 
(140 µL, 1.41 mmol) was added at -15 °C and the reaction was stirred for 3 d at this temperature. Aqueous 
HCl (1 M, 1 mL) was added and the usual work-up (DCM) and purification (10 to 20% EtOAc in hexanes 
with 1.5% Et3N) afforded 18a (51 mg, 40%) as a yellow solid. 1H NMR (300 MHz, CDCl3) δ (ppm) 9.42 
(s, 1H), 6.61 (s, 1H), 6.60 (s, 1H), 3.85 (s 3H), 3.81 (s, 3H), 3.51 (br s, 1H), 3.13 – 2.87 (m, 4H), 2.61 – 
2.47 (m, 2H), 2.40 - 2.30 (m, 2H), 1.72 – 1.50 (m, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 206.1, 
147.8, 147.7, 128.4, 127.3, 111.8, 108.3, 64.0, 57.2, 56.1, 56.0, 52.7, 49.8, 29.5, 26.1, 22.2. IR (neat) ν 
(cm-1) 2936, 2751, 1717, 1517, 1248, 1144, 1002. HRMS (positive ESI) Calcd for C16H22NO3 [MH+]: 
276.1594, found 276.1601. Mp 100 – 104 °C. 
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trans-9,10-Dimethoxy-3,3-dimethyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinoline-1-
carbaldehyde (18b). Following the procedure used to prepare 18a, 16b (103 mg, 0.32 mmol) was treated 
with triflic anhydride (59 µL, 0.35 mmol) and DTBMP (72.7 mg, 0.35 mmol) in CDCl3 (6.20 mL). 1H 
NMR analysis of a small sample of the reaction mixture revealed the presence of iminium ion 17b. 
1H NMR (400 MHz, CDCl3) δ (ppm) 9.82 (s, 1H), 9.13 (s, 1H), 7.57 (s, 1H), 6.87 (s, 1H), 4.02 (s, 3H), 
3.98 (t, J = 8.0 Hz, 2H), 3.94 (s, 3H), 3.87-3.86 (m, 4H), 3.20 (t, J = 8.0 Hz, 2H), 2.64-2.60 (m, 2H), 1.07 
(s, 6H). Subsequent treatment with piperidine (95 µL, 0.96 mmol) for 18 h at -15 °C followed by the usual 
work-up (DCM) and purification (10 to 100% EtOAc in hexanes with 1.5% Et3N) afforded 18b (36 mg, 
37%, 63% brsm) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ (ppm) 9.57 (s, 1H), 6.61 (s, 1H), 6.47 (s, 
1H), 3.85 (s, 3H), 3.78 (s, 3H), 3.37 (s, 1H), 3.19-3.07 (m, 1H), 2.93-2.79 (m, 2H), 2.64-2.52 (m, 3H), 
2.24-2.07 (m, 2H), 1.61–1.55 (m, 1H), 0.92 (s, 3H), 0.90 (s, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ 
(ppm) 207.2 (d), 147.9 (s), 147.7 (s), 128.6 (s), 127.4 (s), 111.8 (d), 108.6 (d), 68.8 (t), 63.4 (d), 56.1 (q), 
56.0 (q), 52.7 (t), 49.2 (d), 41.3 (t), 30.9 (s), 29.7 (t), 29.6 (q), 28.3 (q). IR (neat) ν (cm-1) 2950, 2830, 
2750, 2164, 2052, 1715, 1518. HRMS (positive ESI) Calcd for C18H26NO3 [MH+]: 304.1907, found 
304.1929.  
N-(3,4-Dimethoxyphenethyl)formamide (19). N-Formylbenzotriazole (7.05 g, 43.2 mmol) was added 
to a solution of 3,4-dimethoxyphenethylamine (13, 6.28 mL, 36.1 mmol) dissolved in THF (180 mL) and 
stirred for 18 h at rt. Then the solvent was removed under reduced pressure, the residue was dissolved in 
DCM and washed with aqueous NaOH (2 N, 2 × 45 mL). The usual work-up (DCM) and purification (50 
to 90% EtOAc in hexanes) afforded 19 (7.40 g, 98%) as a yellow oil. 1H NMR (300 MHz, CDCl3) 1:0.2 
mixture of rotamers δ (ppm) 8.15 (s) and 7.96 (d, J = 12 Hz, 1H, rotamers), 6.82 (d, J = 8.0 Hz, 1H), 6.76 
– 6.67 (m, 2H), 5.49 (br s, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.57 (q) and 3.46 (q) (2H, J = 6.6 Hz, rotamers), 
2.80 (t) and 2.76 (t) (2H, J = 7.0 Hz, rotamers). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ 
(ppm) 164.5 (d), 161.2 (d), 149.1 (s), 147.8 (s), 131.1 (s), 120.7 (d), 112.0 (d), 111.5 (d), 56.0 (q), 55.9 
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(q), 43.3 (t), 39.4 (t), 37.4 (t), 35.2 (t). IR (neat) ν (cm-1) 3316, 3054, 2999, 2936, 2835, 1659, 1513, 1258, 
1232, 1024, 766. HRMS (positive ESI) Calcd for C11H15NO3Na [MNa+]: 232.0944, found 232.0946. 
N-(3,4-Dimethoxyphenethyl)-N-methylformamide (20). KHMDS (0.5 M in toluene, 2.40 mL, 
1.20 mmol) was added dropwise to a solution of 19 (201 mg, 0.96 mmol) in THF (5.0 mL). The mixture 
was stirred for 1 h 30 min at rt then DMF (4.80 mL) and MeI (0.24 mL, 3.84 mmol) were added. The 
solution was refluxed for 18 h then allowed to cool to rt and concentrated under reduced pressure. Water 
was added and the usual work-up (EtOAc) and purification (50 to 80% EtOAc in hexanes) afforded 20 
(206 mg, 96%) as an orange oil. Analytical data were in accordance with those reported in the literature.21 
1H NMR (300 MHz, CDCl3) 1:0.6 mixture of rotamers δ (ppm) 7.90 (s) and 7.70 (s) (1H, rotamers), 6.71 
– 6.55 (m, 3H), 3.76 (s) and 3.75 (s) (3H, rotamers), 3.74 (s, 3H), 3.44 (t) and 3.34 (t) (J = 7.0 Hz, 2H, 
rotamers), 2.78 (s) and 2.75 (s) (3H, rotamers), 2.72 – 2.65 (m, 2H). 13C{1H} NMR (75 MHz, CDCl3) 
mixture of rotamers δ (ppm) 162.4 (d), 162.2 (d), 148.9 (s), 148.7 (s), 147.7 (s), 147.4 (s), 130.9 (s), 130.1 
(s), 120.6 (d), 120.5 (d), 111.8 (d), 111.7 (d), 111.3 (d), 111.2 (d), 55.7 (q), 55.6 (q), 51.1 (t), 45.7 (t), 34.8 
(q), 34.2 (t), 32.5 (t), 29.5 (q). IR (neat) ν (cm-1) 2932, 2835, 1661, 1514, 1259, 1233, 1025. 
Iminium ion (21). Following the procedure used to prepare 18a, 13 was treated with triflic anhydride 
and DTBMP in CDCl3. 1H NMR analysis of a small sample of the reaction mixture revealed the presence 
of iminium ion 21. 1H NMR (400 MHz, CDCl3) δ (ppm) 9.05 (s, 1H), 7.40 (s, 1H), 6.84 (s, 1H), 4.00 (s, 
3H), 3.96 (t, J = 8.5 Hz, 2H), 3.90 (s, 3H), 3.78 (s, 3H), 3.24 (t, J = 8.5 Hz, 2H). 
N-(3,4-Dimethoxyphenethyl)-5-hydroxyhexanamide (24). A solution of AlMe3 (2.0 M in toluene, 
20.0 mL, 40 mmol) was added to a solution of 13 (6.80 mL, 40 mmol) in DCM (200 mL) at rt. The 
reaction mixture was stirred for 30 min at rt then a solution of δ-caprolactone (23, 2.20 mL, 20 mmol) 
was added at 0 °C. The solution was stirred for 30 min at 0 °C then for 18 h at rt and finally cooled to 
0 °C. Water was slowly added at 0 °C followed by a saturated solution of potassium sodium tartrate and 
the mixture was stirred vigorously for 4 h at rt. The usual workup (DCM) and purification (70 to 100% 
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EtOAc in hexanes then 5% MeOH in EtOAc) afforded 24 (5.90 g, 99%) as a yellow oil. 1H NMR 
(300 MHz, CDCl3) δ (ppm) 6.79 (d, J = 8.5 Hz, 1H), 6.72 – 6.70 (m, 2H), 5.68 (br s, 1H), 3.85 (s, 3H), 
3.84 (s, 3H), 3.79 – 3.69 (m, 1H), 3.51 – 3.45 (m, 2H), 2.74 (t, J = 7.0 Hz, 2H), 2.20 (br s, 1H), 2.15 (t, J 
= 7.5 Hz, 2H), 1.69 (dt, J = 15.0, 7.0 Hz, 2H), 1.45 – 1.37 (m, 2H), 1.15 (d, J = 6.0 Hz, 3H). 13C{1H} NMR 
(75 MHz, CDCl3) δ (ppm) 173.2 (s), 149.1 (s), 147.7 (s), 131.5 (s), 120.7 (d), 112.0 (d), 111.4 (d), 67.3 
(d), 56.0 (q), 55.9 (q), 40.7 (t), 38.5 (t), 36.3 (t), 35.3 (t), 23.6 (q), 21.7 (t). IR (neat) ν (cm-1) 3304 (br), 
2933, 2837, 1645, 1515, 1260, 1235, 1027. HRMS (positive ESI) Calcd for C16H25NO4Na [MNa+]: 
318.1676, found 318.1678. 
N-(3,4-Dimethoxyphenethyl)-N-(5-hydroxyhexyl)formamide (27). LiAlH4 (4.63 g, 122 mmol) was 
added in small portions to a solution of 24 (18.0 g, 61.0 mmol) in THF (203 mL) at 0 °C and the mixture 
was refluxed for 18 h. The resulting mixture was cooled at 0 °C and quenched with water (4.6 mL). An 
aqueous solution of NaOH (15%, 4.6 mL) and water (12.0 mL) were added, and the mixture was stirred 
vigorously at rt for 5 h. Anhydrous Na2SO4 was added and the mixture was filtered over Celite and 
concentrated under reduced pressure. The residue was used directly in the next step. Following the 
procedure used to prepare 19, crude 25 was treated with N-formylbenzotriazole (18.8 g, 128 mmol) in 
THF (244 mL). The residue was used directly in the next step. K2CO3 was added to crude 26 dissolved in 
MeOH (203 mL). The reaction mixture was refluxed for 18 h then cooled to rt. Water (80 mL) was added 
ant the usual work-up (EtOAc) and purification (30 to 100% EtOAc in hexanes) afforded 27 (13.8 g, 73% 
over 3 steps) as a yellow oil. 1H NMR (300 MHz, CDCl3) 1:0.9 mixture of rotamers δ (ppm) 8.04 (s) and 
7.83 (s) (1H, rotamers), 6.81 – 6.73 (m, 2H), 6.68 – 6.63 (m, 1H), 3.87 (s) and 3.86 (s) (3H, rotamers), 
3.85 (s, 3H), 3.81 – 3.73 (m, 1H), 3.52 – 3.47 (m, 1H), 3.41 (t, J = 7.0 Hz, 1H), 3.33 (t, J = 7.5 Hz, 1H), 
3.11 (t, J = 7.0 Hz, 1H), 2.82 – 2.73 (m, 2H), 1.59 – 1.24 (m, 7H), 1.17 (d, J = 6.0 Hz, 3H). 13C{1H} NMR 
(75 MHz, CDCl3) mixture of rotamers δ (ppm) 163.0 (d), 162.8 (d), 149.3 (s), 149.1 (s), 148.1 (s), 147.8 
(s), 131.5 (s), 130.4 (s), 120.9 (d), 120.8 (d), 112.2 (d), 112.1 (d), 111.6 (d), 111.5 (d), 67.9 (d), 67.8 (d), 
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56.1 (q), 56.0 (q), 49.3 (t), 48.1 (t), 44.4 (t), 42.3 (t), 38.9 (t), 38.8 (t), 35.2 (t), 33.4 (t), 31.0 (t), 28.9 (t), 
27.5 (t), 23.8 (q), 23.7 (q), 23.0 (t), 22.8 (t). IR (neat) ν (cm-1) 3413 (br), 2932, 2859, 1653, 1515, 1026. 
HRMS (positive ESI) Calcd for C17H27NO4Na [MNa+]: 332.1832, found 332.1836. 
N-(3,4-Dimethoxyphenethyl)-N-(5-oxohexyl)formamide (28a). Following the procedure used to 
prepare 16a, 27 (1.02 g, 3.30 mmol) was treated with DMSO (0.61 mL, 8.58 mmol), oxalyl chloride 
(0.42 mL, 4.95 mmol), and triethylamine (2.30 mL, 16.5 mmol) in DCM (13 mL). The usual work-up 
(DCM) and purification (40 to 90% EtOAc in hexanes) afforded 28a (852 mg, 84%) as a yellow oil. 
1H NMR (300 MHz, CDCl3) 1:0.9 mixture of rotamers δ (ppm) 8.05 (s) and 7.82 (s) (1H, rotamers), 6.81 
– 6.73 (m, 2H), 6.68 – 6.62 (m, 1H), 3.87 (s) and 3.86 (s) (3H, rotamers), 3.85 (s, 3H), 3.52 – 3.46 (m, 
1H), 3.41 (t, J = 7.0 Hz, 1H), 3.32 (t, J = 7.0 Hz, 1H), 3.10 (t, J = 6.0 Hz, 1H), 2.82 – 2.73 (m, 2H), 2.49 
– 2.40 (m, 2H), 2.12 (s, 3H), 1.58 – 1.48 (m, 4H). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers 
δ (ppm) 208.6 (s), 208.0 (s), 162.9 (d), 162.8 (d), 149.3 (s), 149.1 (s), 148.1 (s), 147.8 (s), 131.4 (s), 130.4 
(s), 120.9 (d), 120.8 (d), 112.2 (d), 112.1 (d), 111.6 (d), 111.4 (d), 56.0 (q), 49.2 (t), 48.0 (t), 44.4 (t), 43.0 
(t), 42.9 (t), 42.0 (t), 35.2 (t), 33.4 (t), 30.2 (q), 30.1 (q), 28.3 (t), 26.8 (t), 20.9 (t), 20.6 (t). IR (neat) ν 
(cm-1) 2936, 1711, 1665, 1515, 1027. HRMS (positive ESI) Calcd for C17H25NO4 [MNa+]: 330.1675, 
found 330.1681. 
N-(3,4-Dimethoxyphenethyl)-N-(2,2-dimethyl-5-oxohexyl)formamide (28b). Methylmagnesium 
bromide (221 μL, 1.91 mmol) was added dropwise to a solution of 16b (410 mg, 1.27 mmol) in THF 
(6.0 mL) at -78 °C. The mixture was stirred for 3 h at -78 °C then AcOH was added. The reaction was 
allowed to warm up at rt and concentrated under reduced pressure. Saturated aqueous NH4Cl was added. 
The usual work-up (DCM) and purification (40 to 90% EtOAc in hexanes) afforded N-(3,4-
dimethoxyphenethyl)-N-(5-hydroxy-2,2-dimethylhexyl)formamide (113 mg, 26%) as a yellow oil. 
1H NMR (300 MHz, CDCl3) 1:0.6 mixture of rotamers δ (ppm) 8.03 (s) and 7.88 (s) (1H, rotamers), 6.80 
(d, J = 8.5 Hz, 1H), 6.74 – 6.61 (m, 2H), 3.87 (s) and 3.86 (s) (3H, rotamers), 3.85 (s, 3H), 3.77-3.67 (m, 
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1H), 3.63-3.48 (m, 2H), 3.14 (s) and 2.89 (s) (2H, rotamers), 2.79-2.75 (m, 2H), 1,73 (br s, 1H), 1.63-1.09 
(m, 7H), 0.90 (d, J = 16.0 Hz) and 0.89 (d, J = 16.0 Hz) (6H, rotamers). 13C{1H} NMR mixture of rotamers 
(75 MHz, CDCl3) δ (ppm) 164.2 (d), 149.3 (s), 149.1 (s), 148.1 (s), 147.8 (s), 131.6 (s), 130.3 (s), 121.1 
(d), 120.8 (d), 112.2 (d), 112.2 (d), 111.6 (d), 111.5 (d), 68.6 (d), 68.4 (d), 63.3 (t), 58.5 (t), 56.1 (q), 51.5 
(t), 48.0 (t), 36.4 (s), 36.2 (s), 35.9 (t), 35.6 (t), 35.3 (t), 33.6 (t), 33.5 (t), 33.3 (t), 26.6 (q), 26.2 (q), 25.4 
(q), 25.3 (q), 23.9 (q). IR (neat) ν (cm-1) 2958 (br), 2936, 2870, 2162, 2010, 1728, 1660. HRMS (positive 
ESI) Calcd for C19H31NO4Na [M + Na+]: 360.2145, found 360.2147. Following the procedure used to 
prepare 16a, N-(3,4-dimethoxyphenethyl)-N-(5-hydroxy-2,2-dimethylhexyl)formamide (371 mg, 
1.10 mmol) was treated with DMSO (0.20 mL, 2.86 mmol), oxalyl chloride (0.14 mL, 1.65 mmol), and 
triethylamine (0.76 mL, 5.50 mmol) in DCM (8 + 5.5 mL). The usual work-up (DCM) and purification 
(40 to 90% EtOAc in hexanes) afforded 28b (253 mg, 69%) as a yellow oil. 1H NMR (300 MHz, CDCl3) 
1:0.7 mixture of rotamers δ (ppm) 8.03 (s) and 7.88 (s) (1H, rotamers), 6.80 (d, J = 8.5 Hz, 1H), 6.75 – 
6.60 (m, 2H), 6.87 (s, 3H), 6.86 (s, 3H), 3.53 (dt, J = 14.5, 7.0 Hz, 2H), 3.12 (s) and 2.88 (s) (2H, rotamers), 
2.83-2.73 (m, 2H), 2.53-2.34 (m, 2H), 2.15 (s, 3H), 1.55 – 1.45 (m, 2H), 0.91 (s, 3H), 0.85 (s, 3H). 
13C{1H} NMR mixture of rotamers (75 MHz, CDCl3) δ (ppm) 209.1 (s), 208.1 (s), 164.0 (d), 163.9 (d), 
149.2 (s), 149.0 (s), 148.0 (d), 147.7 (s), 131.4 (s), 130.2 (s), 120.9 (d), 120.7 (d), 112.1 (d), 112.0 (d), 
111.5 (d), 111.4 (d), 58.6 (t), 55.9 (q), 51.4 (t), 51.3 (t), 48.0 (t), 38.7 (t), 38.3 (t), 36.0 (s), 35.3 (s), 35.1 
(t), 33.7 (t), 33.7 (t), 33.3 (t), 33.1 (t), 30.0 (q), 26.0 (q), 24.8 (q). IR (neat) ν (cm-1) 2960 and 2941 (br), 
2871, 2833, 2168, 2032, 1712, 1663. HRMS (positive ESI) Calcd for C19H29NO4Na [M + Na+]: 358.1989, 
found 358.1993. 
N-(3,4-Dimethoxyphenethyl)-N-(5-oxohexyl)acetamide (28c). Following the procedure to prepare 
27, 24 (5.32 g, 18.0 mmol) was treated with LiAlH4 (1.37 g, 36.0 mmol) in THF (60 mL), then with water 
(1.37 mL), NaOH (15%, 1.37 mL), and water (4.10 mL) to afford a residue that was used directly in the 
next step. Et3N (1.98 mL, 14.2 mmol) and AcCl (0.53 mL, 7.43 mmol) were added to the residue 
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dissolved in DCM (18 mL) at 0 °C and stirred for 18 h at rt. The residue was washed with a saturated 
solution of NaHCO3 (2 x 25 mL). The usual work-up (DCM) and purification (40 to 100% EtOAc in 
hexanes) afforded 6-(N-(3,4-dimethoxyphenethyl)acetamido)hexan-2-yl acetate (772 mg, 60% over 2 
steps) as a yellow oil. 1H NMR (300 MHz, CDCl3) 1:0.9 mixture of rotamers δ (ppm) 6.82 – 6.75 (m, 
2H), 6.73 – 6.65 (m, 1H), 4.93 – 4.83 (m, 1H), 3.87 (s, 3H), 3.86 (s) and 3.85 (s) (3H, rotamers), 3.51 – 
3.41 (m, 2H), 3.35 – 3.28 (m, 1H), 3.10 (t, J = 7.5 Hz, 1H), 2.82 – 2.75 (m, 2H), 2.09 (s) and 1.90 (s) (3H, 
rotamers), 2.02 (s, 3H), 1.63 – 1.41 (m, 4H), 1.36 – 1.25 (m, 2H), 1.20 (d, J = 6.5 Hz, 3H). 13C{1H} NMR 
mixture of rotamers (75 MHz, CDCl3) δ (ppm) 170.8 (s), 170.7 (s), 170.2 (s), 170.1 (s), 149.1 (s), 148.9 
(s), 147.9 (s), 147.5 (s), 132.0 (s), 130.7 (s), 120.8 (d), 120.7 (d), 112.1 (d), 112.0 (d), 111.5 (d), 111.3 
(d), 70.7 (d), 70.4 (d), 55.9 (q), 55.8 (q), 50.4 (t), 49.4 (t), 48.2 (t), 45.4 (t), 35.7 (t), 35.6 (t), 34.8 (t), 33.6 
(t), 28.7 (t), 27.5 (t), 22.8 (t), 22.7 (t), 21.6 (q), 21.4 (q), 21.3 (q), 19.9 (q), 19.8 (q). IR (neat) ν (cm-1) 
2832, 1864, 1546. HRMS (positive ESI) Calcd for C20H31NO5Na [M + Na+]: 388.2094, found 388.2102. 
K2CO3 (730 mg, 5.28 mmol) was added to a solution of 6-(N-(3,4-dimethoxyphenethyl)acetamido)hexan-
2-yl acetate (772 mg, 2.11 mmol) dissolved in MeOH (7.0 mL) and refluxed for 18 h. Water was added 
and the usual work-up (EtOAc) and purification (60 to 100% EtOAc in hexanes) afforded N-(3,4-
dimethoxyphenethyl)-N-(5-hydroxyhexyl)acetamide (662 mg, 97%) as a colorless oil. 1H NMR 
(300 MHz, CDCl3) 1:0.9 mixture of rotamers δ (ppm) 6.82 – 6.64 (m, 3H), 3.87 (s, 3H), 3.86 (s) and 3.85 
(s) (3H, rotamers), 3.82 – 3.74 (m, 1H), 3.51 – 3.42 (m, 2H), 3.33 (t, J = 7.5 Hz, 1H), 3.12 (t, J = 7.5 Hz, 
1H), 2.82 – 2.75 (m, 2H), 2.08 (s) and 1.91 (s) (3H, rotamers), 1.57 – 1.31 (m, 7H), 1.19 (d, J = 3.0 Hz) 
and 1.17 (d, J = 3.0 Hz) (3H, rotamers). 13C{1H} NMR mixture of rotamers (75 MHz, CDCl3) δ (ppm) 
170.5 (s), 170.2 (s), 149.1 (s), 148.9 (s), 147.9 (s), 147.5 (s), 132.0 (s), 130.7 (s), 120.8 (d), 120.7 (d), 
112.1 (d), 112.0 (d), 111.5 (d), 111.3 (d), 67.6 (d), 67.4 (d), 55.9 (q), 50.5 (t), 49.5 (t), 48.2 (t), 45.5 (t), 
38.9 (t), 38.8 (t), 34.8 (t), 33.6 (t), 29.0 (t), 27.6 (t), 23.7 (q), 23.5 (q), 23.0 (t), 21.6 (q), 21.4 (q). IR (neat) 
ν (cm-1) 3301 (br), 2943, 1648. HRMS (positive ESI) Calcd for C18H29NO4Na [M + Na+]: 346.1989, 
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found 346.1985. Dess-Martin periodinane (2.78 g, 6.56 mmol) was added to a solution of N-(3,4-
dimethoxyphenethyl)-N-(5-hydroxyhexyl)acetamide (662 mg, 2.05 mmol) in DCM (41 mL). The 
reaction mixture was stirred for 2 h 30 min then a saturated aqueous solution of NaHCO3 (20 mL) and 
saturated Na2S2O3 (30 mL) were added and the mixture was stirred for 30 min. The usual workup (DCM) 
and purification (40 to 100% EtOAc in hexanes) afforded 28c (548 mg, 83%) as a yellow oil. 1H NMR 
(300 MHz, CDCl3) 1:0.9 mixture of rotamers δ (ppm) 6.82 – 6.65 (m, 3H), 3.87 (s, 3H), 3.86 (s) and 3.85 
(s) (3H, rotamers), 3.51 – 3.42 (m, 2H), 3.32 (t, J = 7.0 Hz, 1H), 3.11 (t, J = 7.0 Hz, 1H), 2.81 – 2.76 (m, 
2H), 2.49 – 2.42 (m, 2H), 2.13 (s, 3H), 2.08 (s) and 1.90 (s) (3H, rotamers), 1.57 – 1.50 (m, 4H). 
13C{1H} NMR mixture of rotamers (75 MHz, CDCl3) δ (ppm) 208.8 (s), 208.0 (s), 170.3 (s), 170.1 (s), 
149.0 (s), 148.8 (s), 147.8 (s), 147.4 (s), 131.9 (s), 130.7 (s), 120.7 (d), 120.6 (d), 112.0 (d), 111.9 (d), 
111.4 (d), 111.2 (d), 55.9 (q), 55.8 (q), 50.4 (t), 49.3 (t), 48.1 (t), 45.1 (t), 43.1 (t), 42.9 (t), 34.7 (t), 33.6 
(t), 29.9 (q), 28.4 (t), 27.0 (t), 21.6 (q), 21.3 (q), 20.9 (t), 20.7 (t). IR (neat) ν (cm-1) 2834, 1635, 1542. 
HRMS (positive ESI) Calcd for C18H27NO4Na [M + Na+]: 344.1832, found 344.1839. 
N-(3,4-Dimethoxyphenethyl)-N-(2,2-dimethyl-5-oxohexyl)acetamide (28d). 2-(3,4-
Dimethoxyphenyl)ethylamine (4.00 mL, 23.9 mmol) was added to a solution of the aldehyde 12b (6.84 g, 
23.9 mmol) in DCM (50 mL) and stirred for 1 h at rt. Then anhydrous Na2SO4 (6.78 g, 47.7 mmol) was 
added to the reaction and stirred for 1 h 30 min at rt. The resulting mixture was filtered and washed with 
DCM (30 mL). MeOH (66 mL) and sodium borohydride (1.80 g, 47.7 mmol) were added to the reaction, 
stirred for 18 h at rt and quenched with water. The usual work-up (DCM, brine) afforded a residue that 
was used directly in the next step. Pyridine (1.10 mL, 13.2 mmol) was added to the residue dissolved in 
DCM (133 mL) and cooled to 0 °C. Freshly distilled acetyl chloride (0.47 mL, 6.60 mL) was added to the 
reaction and stirred for 1 h at 0 °C then allowed to warm up to rt and stirred for 18 h. Then water was 
added. The usual work-up (DCM) and purification (20 to 40% EtOAc in hexanes) afforded N-(3,4-
dimethoxyphenethyl)-N-(2,2-dimethyl-5-((triisopropylsilyl)oxy)pentyl)acetamide (2.69 g, 83%) as a 
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yellow oil. 1H NMR (300 MHz, CDCl3) 1:0.7 mixture of rotamers δ (ppm) 6.82 – 6.74 (m, 1H), 6.74 – 
6.62 (m, 2H), 3.87 (s, 3H), 3.86 (s) and 3.85 (s) (3H, rotamers), 3.64 (t, J = 6.5 Hz, 2H), 3.58 – 3.50 (m, 
2H), 3.21 (s) and 2.98 (s) (2H, rotamers), 2.83 – 2.73 (m, 2H), 2.10 (s) and 1.99 (s) (3H, rotamers), 1.58 
– 1.44 (m, 2H), 1.29 – 1.24 (m, 2H), 1.05 (s, 21H), 0.91 (s) and 0.89 (s) (6H, rotamers). 13C{1H} NMR 
(75 MHz, CDCl3) mixture of rotamers δ (ppm) 171.7 (s), 171.5 (s), 149.2 (s), 149.0 (s), 148.0 (s), 147.6 
(s), 132.3 (s), 130.9 (s), 120.9 (d), 120.8 (d), 112.3 (d), 112.1 (d), 111.6 (d), 111.4 (d), 64.2 (t), 63.9 (t), 
59.6 (t), 56.1 (q), 56.0 (q), 54.6 (t), 52.5 (t), 50.9 (t), 37.3 (t), 37.1 (t), 36.7 (s), 36.6 (s), 34.7 (t), 33.0 (t), 
27.8 (t), 27.6 (t), 26.1(q), 25.9 (q) , 22.5 (q), 21.7 (q), 18.2 (q), 12.2 (d), 12,1 (d). IR (neat) ν (cm-1) 2937, 
2869, 2147, 1648. HRMS (positive ESI) Calcd for C28H51NO4SiNa [M + Na+]: 516.3480, found 
516.3478. A solution of TBAF (1.0 M in THF, 1.90 mL, 6.54 mmol) was added dropwise to a solution of 
N-(3,4-dimethoxyphenethyl)-N-(2,2-dimethyl-5-((triisopropylsilyl)oxy)pentyl)acetamide (2.69 g, 
5.45 mmol) in THF (7.0 mL) and stirred for 1 h at rt. The solvent was removed under reduced pressure 
and purification (100% EtOAc then 2% MeOH in EtOAc) afforded N-(3,4-dimethoxyphenethyl)-N-(5-
hydroxy-2,2-dimethylpentyl)acetamide (1.62 g, 88%) as a yellow oil. 1H NMR (300 MHz, CDCl3) 1:0.4 
mixture of rotamers δ (ppm) 6.83 – 6.78 (m, 1H), 6.74 – 6.63 (m, 2H), 3.87 (s, 3H), 3.86 (s, 3H), 3.65 – 
3.51 (m, 4H), 3.20 (s) and 3.00 (s) (2H, rotamers), 2.83 – 2.74 (m, 2H), 2.11 (s) and 2.00 (s) (3H, 
rotamers), 1.90 (t, J = 5.0 Hz, 1H), 1.65 – 1.48 (m, 2H), 1.30 – 1.24 (m, 2H), 0.93 (s) and 0.90 (s) (6H, 
rotamers). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ (ppm) 172.0 (s), 171.8 (s), 149.2 (s), 
149.0 (s), 148.0 (s), 147.6 (s), 132.2 (s), 130.7 (s), 120.8 (d), 120.7 (d), 112.3 (d), 112.1 (d), 111.6 (d), 
111.4 (d), 63.3 (t), 63.2 (t), 59.5 (t), 56.1 (q), 56.0 (q), 54.1 (t), 52.7 (t), 51.0 (t), 37.2 (t), 36.7 (s), 36.6 
(s), 36.2 (t), 34.6 (t), 33.0 (t), 27.4 (t), 27.2 (t), 26.4 (q), 25.8 (q), 22.5 (q), 21.8 (q). IR (neat) ν (cm-1) 
3402 (br), 2944, 2150, 2017, 1623. HRMS (positive ESI) Calcd for C19H31NO4Na [M + Na+]: 360.2145, 
found 360.2155. Following the procedure used to prepare 16a, N-(3,4-dimethoxyphenethyl)-N-(5-
hydroxy-2,2-dimethylpentyl)acetamide (1.62 g, 4.80 mmol) was treated with DMSO (0.89 mL, 
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12.5 mmol), oxalyl chloride (0.61 mL, 47.2 mmol), and triethylamine (3.33 mL, 24.0 mmol) in DCM (36 
+ 24 mL). The usual work-up (DCM) and purification (80% EtOAc in hexanes) afforded N-(3,4-
dimethoxyphenethyl)-N-(2,2-dimethyl-5-oxopentyl)acetamide (1.41 g, 88%) as a yellow oil. 1H NMR 
(300 MHz, CDCl3) 1:0.3 mixture of rotamers δ (ppm) 9.76 (t, J = 1.5 Hz, 1H), 6.82 – 6.78 (m, 1H), 6.74 
– 6.62 (m, 2H), 3.87 (s, 3H), 3.86 (s, 3H), 3.53 (t, J = 7.5 Hz, 2H), 3.20 (s) and 2.99 (s) (2H, rotamers), 
2.84 – 2.74 (m, 2H), 2.52 – 2.39 (m, 2H), 2.11 (s) and 2.00 (s) (3H, rotamers), 1.56 – 1.51 (m, 2H), 0.91 
(s) and 0.90 (s) (6H, rotamers). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ (ppm) 171.7 (s), 
171.6 (s), 149.2 (s), 148.9 (s), 148.0 (s), 147.5 (s), 132.0 (s), 130.6 (s), 120.8 (d), 120.7 (d), 112.2 (d), 
112.0 (d), 111.6 (d), 111.3 (d), 59.6 (t), 56.1 (q), 56.0 (q), 54.0 (t), 52.6 (t), 51.1 (t), 39.4 (t), 38.9 (t), 36.3 
(s), 34.5 (t), 32.9 (t), 32.4 (t), 32.0 (t), 26.0 (q), 25.4 (q), 22.4 (q), 21.6 (q). IR (neat) ν (cm-1) 2955, 2872, 
2833, 2057, 1720. HRMS (positive ESI) Calcd for C19H29NO4Na [MNa+]: 358.1989, found 358.1990. 
Methylmagnesium bromide (2.90 mL, 2.51 mmol) was added dropwise to a solution of N-(3,4-
dimethoxyphenethyl)-N-(2,2-dimethyl-5-oxopentyl)acetamide (560 mg, 1.67 mmol) in THF (8.0 mL) at 
-78 °C. The mixture was stirred for 3 h at -78 °C then AcOH was added. The reaction was allowed to 
warm up at rt and concentrated under reduced pressure. Saturated aqueous NH4Cl was added. The usual 
work-up (DCM) and purification (20 to 80% EtOAc in hexanes) afforded N-(3,4-dimethoxyphenethyl)-
N-(5-hydroxy-2,2-dimethylhexyl)acetamide (237 mg, 40%) as a yellow oil. 1H NMR (300 MHz, CDCl3) 
mixture of rotamers δ (ppm) 6.82 – 6.63 (m, 3H), 3.87 (s, 3H), 3.86 (s, 3H), 3.76 – 3.66 (m, 1H), 3.61 – 
3.45 (m, 2H), 3.30 – 2.99 (m, 2H), 2.83 – 2.73 (m, 2H), 2.11 (s) and 1.99 (s) (3H, rotamers), 1.72 (br s, 
1H), 1.65 – 1.10 (m, 7H), 0.91-0.89 (m, 6H). 13C{1H} NMR mixture of rotamers (75 MHz, CDCl3) δ 
(ppm) 172.0 (s), 171.8 (s), 149.3 (s), 149.1 (s), 148.1 (s), 132.3 (s), 130.8 (s), 120.9 (d), 120.8 (d), 112.3 
(d), 112.2 (d), 111.7 (s), 111.4 (s), 68.6 (d), 68.2 (d), 56.1 (q), 53.9 (q),52.8 (t), 37.3 (t), 36.6 (s), 35.7 (t), 
34.7 (t), 33.6 (t), 33.5 (t), 33.1 (t), 26.9 (q), 26.5 (q), 26.3 (q), 26.3(q), 25.6 (q), 23.9 (q), 22.5 (q), 21.8 
(q). IR (neat) ν (cm-1) 2962 (br), 2929, 2868, 2166, 1726, 1628. HRMS (positive ESI) Calcd for 
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C20H33NO4Na [MNa+]: 374.2302, found 374.2306. Following the procedure used to prepare 16a, N-(3,4-
dimethoxyphenethyl)-N-(5-hydroxy-2,2-dimethylhexyl)acetamide (353 mg, 1.00 mmol) was treated with 
DMSO (0.19 mL, 2.60 mmol), oxalyl chloride (0.13 mL, 1.50 mmol), and triethylamine (0.70 mL, 
5.00 mmol) in DCM (8.0 + 5.5 mL). The usual work-up (DCM) and purification (20 to 80% EtOAc in 
hexanes) afforded 28d (232 mg, 66%) as a yellow oil. 1H NMR (300 MHz, CDCl3) mixture of rotamers 
δ (ppm) 6.80 – 6.61 (m, 3H), 3.85 (s, 3H), 3.84 (s, 3H), 3.56 – 3.49 (m, 2H), 3.16 (s) and 2.06 (s) (2H, 
rotamers), 2.81 – 2.71 (m, 2H), 2.49-2.33 (m, 2H), 2.13 (s, 3H), 2.09 (s) and 1.97 (s) (3H, rotamers), 1.54 
– 1.44 (m, 2H), 0.88 (s, 3H), 0.86 (s, 3H). 13C{1H} NMR mixture of rotamers (75 MHz, CDCl3) δ (ppm) 
209.4 (s), 202.9 (s), 171.6 (s), 149.2 (s), 149.0 (s), 148.0 (s), 147.6 (s), 130.7 (s), 130.7 (s), 120.8 (d), 
112.2 (d), 112.1 (d), 111.6 (d), 111.4 (d), 56.1 (q), 56.0 (q), 54.1 (t), 54.0 (t), 52.7 (t), 52.6 (t), 38.9 (t), 
36.3 (s), 34.6 (t), 34.0 (t), 30.1 (q), 30.1 (q), 26.1 (q), 25.4 (q), 21.7 (q). IR (neat) ν (cm-1) 2963 and 2939 
(br), 2871, 2838, 2166, 1975, 1715, 1634. HRMS (positive ESI) Calcd for C20H31NO4 [MNa+]: 372.2145, 
found 372.2149. 
N-(3,4-Dimethoxyphenethyl)-N-(4-oxopentyl)formamide (28e). Following the procedure used to 
prepare 24, 13 (4.05 mL, 24.0 mmol) was treated with AlMe3 (2.0 M in toluene, 12.0 mL, 24.0 mmol) 
and then γ-valerolactone (38, 1.91 mL, 20.0 mmol) in DCM (96 mL). The usual workup (DCM) and 
purification (70 to 100% EtOAc in hexanes then 2 to 9% MeOH in EtOAc) afforded N-(3,4-
dimethoxyphenethyl)-N-(4-hydroxy)pentanamide (4.05 g, 72%) as a white solid. 1H NMR (300 MHz, 
CDCl3) δ (ppm) 6.80 – 6.77 (m, 1H), 6.72 – 6.69 (m, 2H), 5.89 (br s, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 3.80 
– 3.72 (m, 1H), 3.46 (q, J = 13.0, 7.0 Hz, 1H), 3.14 (br s, 1H), 2.74 (t, J = 7.0 Hz, 1H), 2.28 (t, J = 7.0 
Hz, 1H), 1.82 – 1.72 (m, 1H), 1.69 – 1.57 (m, 1H), 1.16 (d, J = 6.0 Hz, 3H). 13C{1H} NMR (75 MHz, 
CDCl3) δ (ppm) 173.7 (s), 149.1 (s), 147.8 (s), 131.4 (s), 120.7 (d), 112.0 (d), 111.5 (d), 67.5 (d), 56.1 
(q), 56.0 (q), 40.9 (t), 35.3 (t), 34.4 (t), 33.4 (t), 23.7 (q). IR (neat) ν (cm-1) 3305 (br), 2976, 1632. HRMS 
(positive ESI) Calcd for C15H23NO4Na [MNa+]: 304.1519, found 304.1511. Mp 70 – 73 °C. Following 
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the procedure to prepare 27, N-(3,4-dimethoxyphenethyl)-N-(4-hydroxy)pentanamide (2.0 g, 7.11 mmol) 
was treated with LiAlH4 (539 mg, 14.2 mmol) in THF (24 mL), then with water (0.54 mL), NaOH (15%, 
0.54 mL), and water (1.62 mL) to afford a residue that was used directly in the next step. Following the 
procedure used to prepare 19, crude the residue was treated with N-formylbenzotriazole (562 mg, 
3.82 mmol) in THF (6.0 mL) then with NaOH (2 M, 2 × 5 mL). The residue was used directly in the next 
step. K2CO3 (528 mg, 3.82 mmol) was added to the residue dissolved in MeOH (6.0 mL) and refluxed for 
18 h. Water was added (10 mL). The usual work-up (EtOAc) and purification (40 to 100% EtOAc in 
hexanes then 3% MeOH in EtOAc) afforded N-(3,4-dimethoxyphenethyl)-N-(4-
hydroxypentyl)formamide (365 mg, 66% over 3 steps) as a colorless oil. 1H NMR (300 MHz, CDCl3) 
1:1 mixture of rotamers δ (ppm) 8.05 (s) and 7.82 (s) (1H, rotamer), 6.81-6.73 (m, 2H), 6.68-6.62 (m, 
1H), 3.87 (s) and 3.86 (s) (3H, rotamers), 3.85 (s, 3H), 3.81-3.72 (m, 1H), 3.53-3.47 (m, 1H), 3.38-3.26 
(m, 1H), 3.43 (t, J = 7.0 Hz, 1H), 3.38-3.26 (m, 1H), 3.14 (t, J = 7.0 Hz, 1H), 2.83-2.74 (m, 2H), 1.90 (br 
s, 1H), 1.75-1.32 (m, 5H), 1.18 (d, J = 6.2 Hz, 1H). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers 
δ (ppm) 162.7 (d), 162.6 (d), 148.8 (s), 148.6 (s), 147.6 (s), 147.3 (s), 131.0 (s), 130.0 (s), 120.6 (d), 120.4 
(d), 111.8 (d), 111.3 (d), 111.1 (d), 66.8 (d), 66.7 (d), 55.6 (q), 55.5 (q), 48.9 (t), 47.8 (t), 43.9 (t), 42.0 (t), 
35.7 (t), 35.4 (t), 34.6 (t), 32.9 (t), 24.7 (t), 23.5 (t), 23.4 (q), 23.3 (q). IR (neat) ν (cm-1) 3402 (br), 2942, 
1644, 1502. HRMS (positive ESI) Calcd for C16H25NO4 [M + Na+]: 318.1676, found 318.1664. Following 
the procedure to prepare 28c, N-(3,4-dimethoxyphenethyl)-N-(4-hydroxypentyl)formamide (365 mg, 
1.24 mmol) was treated with Dess-Martin periodinane (1.68 g, 3.97 mmol) in DCM (24 mL) for 18 h. 
The usual workup (DCM) and purification (40 to 100% EtOAc in hexanes) afforded 28e (295 mg, 81%) 
as a yellow oil. 1H NMR (300 MHz, CDCl3) 1:0.9 mixture of rotamers δ (ppm) 8.01 (s) and 7.82 (s) (1H, 
rotamers), 6.80-6.72 (m, 2H), 6.68-6.63 (m, 1H), 3.87 (s) and 3.86 (s) (3H, rotamers), 3.84 (s, 3H), 3.52-
3.47 (m, 1H), 3.42 (t, J = 7.0 Hz, 1H), 3.34-3.29 (m, 1H), 3.11 (t, J = 7.0 Hz, 1H), 2.82-2.74 (m, 2H), 
2.46 (t, J = 7.0 Hz, 1H), 2.38 (t, J = 6.9 Hz, 1H), 2.13 (s) and 2.12 (s) (3H, rotamers), 1.86-1.72 (m, 2H). 
 38 
13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ (ppm) 208.0 (s), 207.2 (s), 162.9 (d), 162.7 (d), 
149.0 (s), 148.9 (s), 147.8 (s), 147.6 (s), 131.1 (s), 130.2 (s), 120.8 (d), 120.7 (d), 111.9 (d), 111.4 (d), 
111.3 (d), 55.9 (q), 49.0 (t), 46.9 (t), 44.0 (t), 41.3 (t), 40.4 (t), 39.5 (t), 34.9 (t), 33.1 (t), 30.0 (q), 22.3 (t), 
21.3 (t). IR (neat) ν (cm-1) 2902, 1701, 1685, 1512. HRMS (positive ESI) Calcd for C16H23NO4Na [M + 
Na+]: 316.1519, found 316.1524. 
N-(3,4-Dimethoxyphenethyl)-N-(3-oxobutyl)formamide (28f). Following the procedure used to 
prepare 24, 13 (2.50 mL, 15.0 mmol) was treated with AlMe3 (2.0 M in toluene, 7.50 mL, 15.0 mmol) 
and then β-butyrolactone (1.02 mL, 12.5 mmol) in DCM (75 mL). The usual workup (DCM) and 
purification (50 to 100% EtOAc in hexanes then 1 to 3% MeOH in EtOAc) afforded N-(3,4-
dimethoxyphenethyl)-3-hydroxybutanamide (3.32 g, 99%) as a yellow oil. 1H NMR (300 MHz, CDCl3) 
6.81 (d, J = 8.5 Hz, 1H), 6.74-6.71 (m, 2H), 5.71 (br s, 1H), 4.21-4.11 (m, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 
3.58 (d, J = 3.0 Hz, 1H), 3.56-3.48 (m, 2H), 2.77 (t, J = 7.0 Hz, 2H), 2.32-2.17 (m, 2H), 1.20 (d, J = 6.5 
Hz, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 172.4 (s), 148.9 (s), 147.6 (s), 131.3 (s), 120.6 (d), 
111.9 (d), 111.4 (d), 64.8 (d), 55.9 (q), 55.8 (q), 43.9 (t), 40.6 (t), 35.1 (t), 22.8 (q). IR (neat) ν (cm-1) 
3333 (br), 2932, 2833, 1642, 1514, 1259, 1024. HRMS (positive ESI) Calcd for C14H21NO4Na [M + Na+]: 
290.1363, found 290.1368. Following the procedure to prepare 27, N-(3,4-dimethoxyphenethyl)-3-
hydroxybutanamide (3.37 g, 12.6 mmol) was treated with LiAlH4 (956 mg, 25.2 mmol) in THF (42 mL), 
then with water (0.96 mL), NaOH (15%, 0.96 mL), and water (2.88 mL). The usual purification (60 to 
100% EtOAc in hexanes then 3 to 6% MeOH in EtOAc with 1.5% Et3N) afforded N-(3,4-
dimethoxyphenethyl)-N-methyl-5-oxohexanamide (3.0 g, 94%) as a yellow oil. 1H NMR (300 MHz, 
CDCl3) δ (ppm) 6.80 (d, J = 8.0 Hz, 1H), 6.74-6.71 (m, 2H), 4.02-3.92 (m, 1H), 3.87 (s, 3H), 3.85 (s, 
3H), 3.67 (br s, 2H), 3.02-2.72 (m, 6H), 1.63-1.41 (m, 2H), 1.16 (d, J = 6.0 Hz, 3H). 13C{1H} NMR 
(75 MHz, CDCl3) δ (ppm) 149.1 (s), 147.7 (s), 132.1 (s), 120.7 (d), 112.0 (d), 111.5 (d), 69.6 (d), 56.1 
(q), 56.0 (q), 50.9 (t), 48.8 (t), 36.6 (t), 35.7 (t), 23.7 (q). IR (neat) ν (cm-1) 3348 (br), 2960, 2932, 2836, 
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1514, 1260. HRMS (positive ESI) Calcd for C14H24NO3 [M + H+]: 254.1751, found 254.1755. Following 
the procedure used to prepare 19, N-(3,4-dimethoxyphenethyl)-N-methyl-5-oxohexanamide (1.48 g, 
5.84 mmol) was treated with N-formylbenzotriazole (1.81 g, 12.3 mmol) in THF (19 mL) then with 
NaOH (2 M, 2 × 25 mL). The usual work-up (DCM) and purification (50 to 100% EtOAc in hexanes then 
1 to 4% MeOH in EtOAc) afforded N-(3,4-dimethoxyphenethyl)-N-(3-hydroxybutyl)formamide (1.63 g, 
99%) as a colorless oil. 1H NMR (300 MHz, CDCl3) 1:0.3 mixture of rotamers δ (ppm) 8.10 (s) and 7.84 
(s) (1H, rotamers), 6.82-6.62 (m, 3H), 3.96-3.90 (m, 1H), 3.88 (s) and 8.87 (s) (3H, rotamers), 3.86 (s, 
3H), 3.77 (br s, 1H), 3.65-3.55 (m, 2H), 3.44 (t, J = 7.0 Hz, 2H), 3.39-3.02 (m, 1H), 2.84-2.77 (m, 2H), 
1.59-1.43 (m, 1H), 1.22-1.18 (m, 3H). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ (ppm) 
163.6 (d), 163.0 (d), 149.0 (s), 148.8 (s), 147.8 (s), 147.5 (s), 131.2 (s), 129.9 (s), 120.7 (d), 120.6 (d), 
111.9 (d), 111.8 (d), 111.4 (d), 111.2 (d), 64.1 (d), 63.8 (d), 55.8 (q), 55.7 (q), 49.4 (t), 44.6 (t), 44.1 (t), 
39.4 (t), 37.5 (t), 36.7 (t), 34.8 (t), 33.1 (t), 23.8 (q), 22.7 (q). IR (neat) ν (cm-1) 3402 (br), 2946, 2841, 
1651, 1515, 1025. HRMS (positive ESI) Calcd for C15H23NO4Na [M + Na+]: 304.1519, found 304.1518. 
Following the procedure used to prepare 16a, N-(3,4-dimethoxyphenethyl)-N-(3-
hydroxybutyl)formamide (1.63 g, 5.79 mmol) was treated with DMSO (1.07 mL, 15.0 mmol), oxalyl 
chloride (0.75 mL, 8.69 mmol), and triethylamine (4.04 mL, 29.0 mmol) in DCM (43 + 23 mL). The usual 
work-up (DCM) and purification (40 to 100% EtOAc in hexanes then 1 to 4% MeOH in EtOAc) afforded 
28f (1.51 g, 93%) as a white solid. 1H NMR (300 MHz, CDCl3) 1:0.6 mixture of rotamers δ (ppm) 8.06 
(s) and 7.71 (s) (1H, rotamers), 6.75 (d, J = 8.0 Hz, 1H), 6.60-6.60 (m, 2H), 3.82 (s) and 3.81 (s) (3H, 
rotamers), 3.79 (s, 3H), 3.50-3.34 (m, 4H), 2.77-2.69 (m, 3H), 2.53 (t, J = 6.5 Hz, 1H), 2.10 (s) and 2.06 
(s) (3H, rotamers). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ (ppm) 206.9 (s), 205.6 (s), 
163.1 (d), 162.8 (d), 149.0 (s), 148.8 (s), 147.7 (s), 147.5 (s), 131.1 (s), 130.1 (s), 120.8 (d), 120.6 (d), 
111.9 (d), 111.8 (d), 111.4 (d), 111.2 (d), 55.8 (q), 49.9 (t), 44.5 (t), 42.1 (t), 42.0 (t), 41.4 (t), 37.8 (t), 
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35.0 (t), 33.0 (t), 30.2 (q), 29.9 (q). IR (neat) ν (cm-1) 3507, 2934, 2836, 1710, 1655, 1514, 1025. HRMS 
(positive ESI) Calcd for C15H21NO4Na [M + Na+]: 302.1363, found 302.1364. Mp 75 – 77 °C. 
cis-1-(9,10-Dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-1-yl)ethan-1-one 
(30a). Following the procedure used to prepare 18a, 28a (107.6 mg, 0.35 mmol) was treated with triflic 
anhydride (66 µL, 0.39 mmol) and DTBMP (80 mg, 0.39 mmol) in CHCl3 (7.0 mL). 1H NMR analysis of 
a small sample of the reaction mixture revealed the presence of iminium ion 29. 1H NMR (300 MHz, 
CD2Cl2) δ (ppm) 8.97 (s, 1H), 7.39 (s, 1H), 6.85 (s, 1H), 3.97-3.77 (m, 10H), 3.21 (t, J = 8.0 Hz, 2H), 
2.56 (t, J = 6.5 Hz, 2H), 2.11 (s, 3H), 1.91-1.81 (m, 2H), 1.65-1.58 (m, 2H). Subsequent treatment with 
pyrrolidine (88 µL, 1.05 mmol) added at 0 °C then stirred at rt for 18 h followed by the usual work-up 
(DCM) and purification (8 to 70% EtOAc in hexanes with 1.5% Et3N) afforded 30a (74 mg, 73%) as a 
yellow solid. 1H NMR (300 MHz, CDCl3) δ (ppm) 6.57 (s, 1H), 6.43 (s, 1H), 3.96 (d, J = 10.0 Hz, 1H), 
3.83 (s, 3H), 3.74 (s, 3H), 3.26 – 3.18 (m, 1H), 3.06 – 2.89 (m, 3H), 2.84 (t, J = 6.0 Hz, 2H), 2.77 – 2.70 
(m, 1H), 2.04 (s, 3H), 1.90 – 1.45 (m, 4H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 213.6 (s), 147.8 (s), 
146.8 (s), 129.1 (s), 126.7 (s), 111.7 (d), 110.2 (d), 61.7 (d), 55.9 (q), 55.8 (q), 54.7 (t), 51.5 (d), 46.9 (t), 
32.5 (q), 29.1 (t), 29.0 (t), 20.2 (t). IR (neat) ν (cm-1) 2930, 2856, 1701, 1516, 1265, 1227, 1019. HRMS 
(positive ESI) Calcd for C17H24NO3 [MH+]: 290.1750, found 290.1756. Mp 98 – 101 °C. 
cis-1-(9,10-Dimethoxy-3,3-dimethyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-1-
yl)ethan-1-one (30b). Following the procedure used to prepare 18a, 28b (117. mg, 0.35 mmol) was 
treated with triflic anhydride (66 µL, 0.39 mmol) and DTBMP (80 mg, 0.39 mmol) in CHCl3 (7.0 mL). 
1H NMR analysis of a small sample of the reaction mixture revealed the presence of an iminium ion 
resulting from the Vilsmeier-Haack cyclization. 1H NMR (300 MHz, CDCl3) δ (ppm) 8.94 (s, 1H), 7.47 
(s, 1H), 6.90 (s, 1H), 4.01 (s, 3H), 4.00-3.94 (m, 2H), 3.91 (s, 3H), 3.86-3.80 (m, 2H), 3.19 (t, J = 8.0 Hz, 
2H), 2.59-2.54 (m, 2H), 2.18 (s, 3H), 1.65-1.60 (m, 2H), 1.04 (s, 6H). Subsequent treatment with 
pyrrolidine (175 µL, 2.10 mmol) added at 0 °C then stirred at rt for 18 h followed by the usual work-up 
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(DCM) and purification (5 to 20% EtOAc in hexanes with 1.5% Et3N) afforded 30b (81 mg, 73%) as a 
yellow solid. 1H NMR (300 MHz, CDCl3) δ (ppm) 6.56 (s, 1H), 6.48 (s, 1H), 3.83 (s, 3H), 3.74 (s, 3H), 
3.62 (d, J = 10.0 Hz, 1H), 3.07-2.87 (m, 3H), 2.65-2.50 (m, 3H), 2.36-2.32 (m, 1H), 2.25 (s, 3H), 1.62-
1.56 (m, 1H), 1.47-1.39 (m, 1H), 1.08 (s, 3H), 0.92 (s, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 
214.0 (s), 147.4 (s), 146.7 (s), 129.3 (s), 128.4 (s), 111.8 (d), 109.6 (d), 67.6 (t), 63.9 (d), 55.9 (q), 55.8 
(q), 53.1 (d), 52.5 (t), 43.2 (t), 31.7 (q), 30.4 (s), 30.0 (t), 29.4 (q), 25.3 (q). IR (neat) ν (cm-1) 2943, 1704, 
1516, 1256. HRMS (positive ESI) Calcd for C19H28NO3 [M + H+]: 318.2064, found 318.2068. Mp 98 – 
100 °C. 
cis-1-(9,10-Dimethoxy-11b-methyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-1-
yl)ethan-1-one (30c). Following the procedure used to prepare 18a, 28c (97 mg, 0.30 mmol) was treated 
with triflic anhydride (56 µL, 0.33 mmol) and DTBMP (68 mg, 0.33 mmol) in CHCl3 (6.0 mL). 1H NMR 
analysis of a small sample of the reaction mixture revealed the presence of an iminium ion resulting from 
the Vilsmeier-Haack cyclization. 1H NMR (300 MHz, CDCl3) δ (ppm) 7.23 (s, 1H), 6.82 (s, 1H), 4.00-
3.87 (m, 10H), 3.12 (t, J = 7.5 Hz, 2H), 2.82 (s, 3H), 2.60 (t, J = 7.0 Hz, 2H), 2.16 (s, 3H), 1.92-1.81 (m, 
2H), 1.72-1.65 (m, 2H). Subsequent treatment with pyrrolidine (0.15 mL, 1.80 mmol) added at 0 °C then 
stirred at rt for 18 h followed by the usual work-up (DCM) and purification (5 to 35% EtOAc in hexanes 
with 1.5% Et3N) afforded 30c (22 mg, 24%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ (ppm) 6.54 
(s, 1H), 6.53 (s, 1H), 3.84 (s, 3H), 3.75 (s, 3H), 3.45 – 3.29 (m, 2H), 3.26 – 2.16 (m, 2H), 2.91 – 2.72 (m, 
4H), 2.17 (s, 3H), 3.09 (s, 3H), 1.64 (s, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 214.1 (s), 147.4 
(s), 146.8 (s), 134.8 (s), 126.6 (s), 111.6 (d), 109.7 (d), 59.6 (s), 55.9 (q), 55.8 (q), 54.0 (d), 49.4 (t), 45.9 
(t), 34.1 (q), 30.0 (t), 25.6 (t), 21.0 (t), 19.1 (q). IR (neat) ν (cm-1) 2929, 2845, 1701, 1514, 1254. HRMS 
(positive ESI) Calcd for C18H26NO3 [M + H+]: 304.1907, found 304.1910. 
cis-1-(9,10-Dimethoxy-3,3,11b-trimethyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-1-
yl)ethan-1-one (30d). Following the procedure used to prepare 18a, 28d (76.5 mg, 0.22 mmol) was 
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treated with triflic anhydride (40 µL, 0.24 mmol) and DTBMP (49 mg, 0.24 mmol) in DCM (4.4 mL). 1H 
NMR analysis of a small sample of the reaction mixture revealed the presence of an iminium ion resulting 
from the Vilsmeier-Haack cyclization. 1H NMR (300 MHz, CDCl3) δ (ppm) 7.51 (s, 1H), 6.84 (s, 1H), 
4.02-4.00 (m, 5H), 3.94 (s, 3H), 3.89-3.81 (m, 2H), 3.14-3.09 (m, 2H), 2.86 (s, 3H), 2.60-2.54 (m, 2H), 
2.20 (s, 3H), 1.72-1.67 (m, 2H), 1.15 (s, 3H), 1,09 (s, 3H). Subsequent treatment with pyrrolidine (55 µL, 
0.66 mmol) added at 0 °C then stirred at rt for 18 h followed by the usual work-up (DCM) and purification 
(2 to 10% EtOAc in hexanes with 1.5% Et3N) afforded 30d (13 mg, 18%) as a yellow oil. 1H NMR 
(300 MHz, CDCl3) δ (ppm) 6.59 (s, 1H), 6.54 (s, 1H), 3.84 (s, 3H), 3.74 (s, 3H), 3.10 (dd, J = 13.0, 3.0 
Hz, 1H), 3.05-2.83 (m, 3H), 2.61-2.46 (m, 2H), 2.18 (dd, J = 12.0, 2.0 Hz, 1H), 2.12 (s, 3H), 1.70 (t, J = 
13.5 Hz, 1H), 1.46 (s, 3H), 1.34-1.25 (m, 1H), 1.09 (s, 3H), 0.91 (s, 3H). 13C{1H} NMR (75 MHz, CDCl3) 
δ (ppm) 214.7 (s), 147.2 (s), 146.8 (s), 136.0 (s), 127.8 (s), 111.7 (d), 109.8 (d), 61.5 (t), 60.8 (s), 55.9 (q), 
55.8 (q), 55.4 (d), 47.4 (t), 39.9 (t), 33.9 (q), 31.2 (t), 30.3 (s), 29.4 (q), 26.2 (q), 13.4 (q). IR (neat) ν (cm-
1) 2948, 2823, 1703, 1514, 1254. HRMS (positive ESI) Calcd for C20H30NO3 [M + H+]: 332.2220, found 
332.2221. 
cis-1-(8,9-Dimethoxy-1,2,3,5,6,10b-hexahydropyrrolo[2,1-a]isoquinolin-1-yl)ethan-1-one (30e). 
Following the procedure used to prepare 18a, 28e (88 mg, 0.30 mmol) was treated with triflic anhydride 
(56 µL, 0.33 mmol) and DTBMP (68 mg, 0.33 mmol) in DCM (6.0 mL). 1H NMR analysis of a small 
sample of the reaction mixture revealed the presence of an iminium ion resulting from the Vilsmeier-
Haack cyclization. 1H NMR (300 MHz, CDCl3) δ (ppm) 9.04 (s, 1H), 7.41 (s, 1H), 6.86 (s, 1H), 4.00-
3.94 (m, 7H), 3.90 (s, 3H), 3.23 (t, J = 8.5 Hz, 2H), 2.69 (t, J = 6.5 Hz, 2H), 2.14 (s, 3H), 2.13-2.06 (m, 
2H). Subsequent treatment with pyrrolidine (75 µL, 0.90 mmol) added at 0 °C then stirred at rt for 18 h 
followed by the usual work-up (DCM) and purification (10 to 70% EtOAc in hexanes with 1.5% Et3N) 
afforded 30e (79 mg, 95%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ (ppm) 6.58 (s, 1H), 6.45 (s, 
1H), 4.15 (d, J = 8.0 Hz, 1H), 3.84 (s, 3H), 3.78 (s, 3H), 3.13-3.01 (m, 3H), 2.96-2.69 (m, 4H), 2.42-2.32 
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(m, 1H), 2.29 (s, 3H), 1.97-1.85 (m, 1H). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ (ppm) 
210.5 (s), 147.7 (s), 147.5 (s), 129.5 (s), 126.2 (s), 111.5 (d), 109.1 (d), 63.6 (d), 57.9 (d), 56.1 (q), 56.0 
(q), 52.7 (t), 47.5 (t), 30.1 (q), 28.8 (t), 27.4 (t). IR (neat) ν (cm-1) 2928, 2831, 1703, 1511, 1255, 1013. 
HRMS (positive ESI) Calcd for C16H22NO3 [M + H+]: 276.1594, found 276.1598. 
9,10-Dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one (30f). Following the 
procedure used to prepare 18a, 28f (100 mg, 0.36 mmol) was treated with triflic anhydride (67 µL, 
0.40 mmol) and DTBMP (82 mg, 0.40 mmol) in DCM (7.2 mL). Subsequent treatment with pyrrolidine 
(45 µL, 0.54 mmol) added at 0 °C then stirred at rt for 18 h followed by the usual work-up (DCM) and 
purification (5 to 90% EtOAc in hexanes with 1.5% Et3N) afforded 30f (28 mg, 30%) as a orange solid. 
1H NMR (300 MHz, CDCl3) δ (ppm) 6.61 (s, 1H), 6.53 (s, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 3.60-3.53 (m, 
1H), 3.34-3.24 (m, 1H), 3.15-3.13 (m, 2H), 2.91 (d, J = 14.0 Hz, 1H), 2.81-2.42 (m, 6H). 13C{1H} NMR 
(75 MHz, CDCl3) δ (ppm) 208.5 (s), 148.0 (s), 147.7 (s), 128.3 (s), 126.1 (s), 111.6 (d), 107.9 (d), 61.6 
(d), 56.1 (q), 56.0 (q), 54.8 (t), 50.9 (t), 47.5 (t), 41.1 (t), 29.2 (t). IR (neat) ν (cm-1) 2924, 1712, 1514. 
HRMS (positive ESI) Calcd for C15H20NO3 [M + H+]: 262.1438, found 262.1439. Mp 148 – 151 °C. 
2-(1H-Pyrrol-1-yl)ethan-1-ol (36). Ethanolamine (66 mL, 1.09 mmol) was added to glacial acetic acid 
(120 mL) at 0 °C a rate such that the temperature was maintained at 15-25 °C. Then, 2,5-
dimethoxytetrahydrofuran (32 mL, 0.25 mmol) was added in one portion and the reaction was stirred at 
110-120 °C, at which point distillation of a liquid commenced. After 1 h 30 min at that temperature, 
25 mL of a distillate was collected. The residual liquid in the reaction vessel was cooled to rt and water 
was added. The usual work-up (DCM, brine, saturated aqueous Na2CO3) afforded a residue that was 
dissolved in MeOH (67 mL). NaOH (20 wt %, 33 mL) was added and the solution was stirred at rt for 
1 h, then poured into brine and extracted with DCM. The solvent was removed under reduced pressure to 
afford 36 (17 g, 61%) as a yellow oil. Analytical data were in accordance with those reported in the 
literature.22 1H NMR (300 MHz, CDCl3) δ (ppm) 6.71-6.70 (m, 2H), 6.19-6.18 (m, 2H), 4.02 (t, J = 5.0 
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Hz, 2H), 3.84 (t, J = 5.0 Hz, 2H), 1.73 (s, 1H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 120.8 (d), 108.2 
(d), 62.5 (t), 51.7 (t). IR (neat) ν (cm-1) 3401 (br), 2927, 2881. HRMS (positive ESI) Calcd for C6H9NONa 
[MNa+]: 134.0576, found 134.0571. 
1-(2-Iodoethyl)-1H-pyrrole (37). Iodide (1.40 g, 5.50 mmol) was added in three portions to a solution 
of triphenylphosphine (1.43 g, 5.45 mmol) and imidazole (450 mg, 6.60 mmol) in DCM (55 mL) at 0 °C, 
protected from the light. The mixture was stirred for 30 min at 0 °C then a solution of 36 (611 mg, 
5.50 mmol) in DCM (6.0 mL) was added. The reaction mixture was stirred for 18 h at rt then saturated 
aqueous Na2S2O3 was added. The usual work-up (DCM) and purification (10 to 20% DCM in hexanes) 
afforded 37 (968 mg, 79%) as a yellow oil. Analytical data were in accordance with those reported in the 
literature.23 1H NMR (300 MHz, CDCl3) δ (ppm) 6.71-6.70 (m, 2H), 6.22-6.21 (m, 2H), 4.27 (t, J = 7.5 
Hz, 2H), 3.41 (t, J = 7.5 Hz, 2H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 120.4 (d), 108.8 (d), 51.9 (t), 
3.4 (t). IR (neat) ν (cm-1) 1495, 1276, 721. HRMS (positive ESI) Calcd for C6H9NI [MH+]: 221.9774, 
found 221.9764. 
N-(2-(1H-Pyrrol-1-yl)ethyl)-N-(4-oxopentyl)formamide (39a). K2CO3 (4.50 g, 32.4 mmol) was 
added to a solution of 37 (2.38 g, 10.8 mmol) and 38a (1.11 g, 10.8 mmol) in THF (36 mL) in a sealed 
tube. The reaction mixture was stirred for 18 h at 90 °C, then K2CO3 was filtered and solvent was removed 
under reduced pressure to afford crude alkylated amine that was used directly in the next step. Following 
the procedure used to prepare 19, the residue was treated with N-formylbenzotriazole (3.18 g, 21.6 mmol) 
in THF (27 mL) then with NaOH (2 M). The usual work-up (DCM) afforded a crude N,O-bisformylated 
product that was used directly in the next step. K2CO3 (4.48 g, 32.4 mmol) was added to a solution of the 
residue in MeOH (35 mL). The reaction mixture was refluxed for 2 h then allowed to cool to rt. Water 
was added and the usual work-up (EtOAc) afforded crude hydroxy-formamide that was used directly in 
the next step. Following the procedure to prepare 28c, the residue was treated with Dess-Martin 
periodinane in DCM (20 mL) for 18 h. The usual workup (DCM) and purification (20 to 80% EtOAc in 
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hexanes) afforded 39a (354 mg, 56% over 4 steps) as an orange oil. 1H NMR (300 MHz, CDCl3) 1:0.6 
mixture of rotamers δ (ppm) 8.04 (s) and 7.53 (s) (1H, rotamers), 6.64-6.57 (m, 2H), 6.16-6.12 (m, 2H), 
4.09 (t, J = 6.0 Hz, 1H), 4.02-3.99 (m, 1H), 3.57-3.49 (m, 2H), 3.26-3.21 (m, 1H), 2.81-2.76 (m, 1H), 
2.45 (t, J = 7.0 Hz, 1H), 2.30 (t, J = 7.0 Hz, 1H), 2.14 (s) and 2.11 (s) (3H, rotamers), 1.83-1.74 (m, 1H), 
1.67-1.57 (m, 1H). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ (ppm) 207.9 (s), 207.1 (s), 
162.9 (d), 162.7 (d), 120.6 (d), 120.4 (d), 109.2 (d), 108.7 (d), 48.6 (t), 48.0 (t), 47.2 (t), 46.9 (t), 44.5 (t), 
41.3 (t), 40.2 (t), 39.5 (t), 30.1 (q), 30.0 (q), 22.2 (t), 21.2 (t). IR (neat) ν (cm-1) 3458 (br), 1707, 1652, 
730. HRMS (positive ESI) Calcd for C12H18N2O2Na [MNa+]: 245.1260, found 245.1267. 
N-(2-(1H-Pyrrol-1-yl)ethyl)-N-(5-oxohexyl)formamide (39b). Following the procedure used to 
prepare 39a, 38b (1.22 g, 10.4 mmol) was treated with K2CO3 (4.30 g, 31.2 mmol) and 37 (2.29 g, 
10.4 mmol) in THF (35 mL) to afford a crude alkylated amine that was used directly in the next step. The 
residue was then treated with N-formylbenzotriazole (3.06 g, 20.8 mmol) in THF (26 mL) to afford crude 
N,O-bisformylated product that was used directly in the next step. The residue then treated with K2CO3 
(4.31 g, 31.2 mmol) in MeOH (35 mL) and the usual work-up (EtOAc) and purification (20 to 100% 
EtOAc in hexanes with 1.5% Et3N, then 5% MeOH in EtOAc with 1.5% Et3N) afforded N-(2-(1H-pyrrol-
1-yl)ethyl)-N-(5-hydroxyhexyl)formamide (1.52 g, 61% over 3 steps) as an orange oil. 1H NMR 
(300 MHz, CDCl3) 1:0.5 mixture of rotamers δ (ppm) 8.07 (s) and 7.57 (s) (1H, rotamers), 6.64-6.58 (m, 
2H), 6.18-6.14 (m, 2H), 4.11-3.97 (m, 2H), 3.82-3.69 (m, 1H), 3.57-3.48 (m, 2H), 3.28-3.23 (m, 1H), 2.81 
(t, J = 7.0 Hz, 1H), 1.55-1.25 (m, 7H), 1.18 (d, J = 6.0 Hz) and 1.17 (d, J = 6.0 Hz) (3H, rotamers). 
13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ (ppm) 163.0 (d), 162.7 (d), 120.6 (d), 120.5 (d), 
109.3 (d), 108.8 (d), 67.6 (d), 67.5 (d), 48.8 (t), 48.3 (t), 48.2 (t), 47.0 (t), 44.7 (t), 42.3 (t), 38.7 (t), 38.5 
(t), 28.6 (t), 27.4 (t), 23.6 (q), 23.5 (q), 22.9 (t), 22.6 (t). IR (neat) ν (cm-1) 3410 (br), 2934, 2860, 1657, 
724. HRMS (positive ESI) Calcd for C13H22N2O2Na [MNa+]: 261.1573, found 261.1576. Following the 
procedure to prepare 28c, N-(2-(1H-pyrrol-1-yl)ethyl)-N-(5-hydroxyhexyl)formamide (83 mg, 
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0.35 mmol) was treated with Dess-Martin periodinane (297 mg, 0.70 mmol) in DCM (7.0 mL) for 18 h. 
The usual workup (DCM) and purification (20 to 80% EtOAc in hexanes) afforded 39b (41 mg, 49%) as 
a yellow oil. 1H NMR (300 MHz, CDCl3) 1:0.6 mixture of rotamers δ (ppm) 8.06 (s) and 7.55 (s) (1H, 
rotamers), 6.63-6.57 (m, 2H), 6.17-6.13 (m, 2H), 4.09 (t, J = 6.0 Hz, 1H), 3.99 (t, J = 6.0 Hz, 1H), 3.56-
3.48 (m, 2H), 3.23 (t, J = 6.5 Hz, 1H), 2.78 (t, J = 7.0 Hz, 1H), 2.46 (t, J = 6.5 Hz, 1H), 2.38 (t, J = 7.0 
Hz, 1H), 2.13 (s) and 2.11 (s) (3H, rotamers), 1.54-1.19 (m, 4H). 13C{1H} NMR (75 MHz, CDCl3) 
mixture of rotamers δ (ppm) 208.6 (s), 208.0 (s), 163.1 (d), 162.8 (d), 120.8 (d), 120.6 (d), 109.5 (d), 
108.9 (d), 48.9 (t), 48.4 (t), 48.3 (t), 47.2 (t), 45.0 (t), 42.9 (t), 42.8 (t), 42.1 (t), 30.2 (q), 30.1 (q), 28.1 (t), 
26.9 (t), 20.8 (t), 20.5 (t). IR (neat) ν (cm-1) 2938, 2866, 1711, 1664, 727. HRMS (positive ESI) Calcd 
for C13H20N2O2Na [MNa+]: 259.1417, found 259.1418. 
N-(2-(1H-pyrrol-1-yl)ethyl)-N-(5-oxohexyl)acetamide (39c). Following the procedure used to 
prepare 39a, 38b (870 mg, 7.42 mmol) was treated with K2CO3 (3.08 g, 22.3 mmol) and 37 (1.64 g, 
7.42 mmol) in THF (25 mL) to afford a crude alkylated amine that was used directly in the next step. The 
residue was dissolved in DCM (37 mL) at 0 °C and Et3N (4.14 mL, 29.7 mmol) was added, followed by 
a dropwise addition of acetyl chloride (1.11 mL, 15.6 mmol). The reaction mixture was stirred for 18 h at 
rt then quenched and washed with a saturated aqueous solution of NaHCO3 (2 × 25 mL). The usual 
workup (DCM) afforded crude N,O-bisacetylated product that was used directly in the next step. 
Following the procedure used to prepare 39a, the residue then treated with K2CO3 (3.08 g, 22.3 mmol) in 
MeOH (25 mL) and the usual work-up (EtOAc) and purification (20 to 100% EtOAc in hexanes with 
1.5% Et3N, then 5% MeOH in EtOAc with 1.5% Et3N) afforded crude hydroxy-acetamide that was used 
directly in the next step. Following the procedure to prepare 28c, the residue was treated with Dess-Martin 
periodinane (1.0 g, 2.36 mmol) in DCM (16 mL) and the usual workup (DCM) and purification (10 to 
100% EtOAc in hexanes with 1.5% Et3N) afforded 39c (142 mg, 29% over 4 steps) as a yellow oil. 
1H NMR (300 MHz, CDCl3) 1:0.4 mixture of rotamers δ (ppm) 6.62-6.57 (m, 2H), 6.16-6.12 (m, 2H), 
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4.08 (t, J = 6.0 Hz) and 4.01 (t, J = 6.0 Hz) (2H, rotamers), 3.53 (t, J = 6.0 Hz, 2H), 3.25 (t, J = 7.0 Hz, 
1H), 2.80-2.75 (m, 1H), 2.46 (t, J = 6.5 Hz, 1H), 2.38 (t, J = 7.0 Hz, 1H), 2.13 (s) and 2.12 (s) (3H, 
rotamers), 2.08 (s) and 1.63 (s) (3H, rotamers), 1.54-1.25 (m, 4H). 13C{1H} NMR (75 MHz, CDCl3) 
mixture of rotamers δ (ppm) 208.5 (s), 207.9 (s), 170.7 (s), 170.4 (s), 120.6 (d), 109.1 (d), 108.5 (d), 49.9 
(t), 49.6 (t), 48.3 (t), 47.8 (t), 47.3 (t), 44.8 (t), 42.9 (t), 42.7 (t), 29.9 (q), 27.9 (t), 26.8 (t), 21.4 (q), 20.8 
(t), 20.6 (t), 20.5 (q). IR (neat) ν (cm-1) 2941, 1709, 1636, 1419. HRMS (positive ESI) Calcd for 
C14H22N2O2Na [MNa+]: 273.1573, found 273.1572. 
2-(3-Iodopropyl)-2-methyl-1,3-dioxolane (41). Iodide (327 mg, 1.29 mmol) was added in three 
different portions to a solution of triphenylphosphine (336 mg, 1.28 mmol) and imidazole (106 mg, 
1.55 mmol) in DCM (13 mL) at 0 °C, protected from the light. After stirring for 30 min at 0 °C, a solution 
of 40 (188 mg, 1.29 mmol) in DCM (1.5 mL) was added. The reaction was stirred for 18 h at rt. Saturated 
aqueous NaHSO3 was added. The usual work-up (Et2O) and purification (50 to 100% EtOAc in hexanes) 
afforded 41 (276 mg, 84%) as a colorless oil. Analytical data were in accordance with those reported in 
the literature.24 1H NMR (300 MHz, CDCl3) δ (ppm) 3.96-3.91 (m, 4H), 3.21 (t, J = 7.0 Hz, 2H), 2.00-
1.90 (m, 2H), 1.77-1.72 (m, 2H), 1.32 (s, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 109.5 (s), 64.8 
(t), 39.9 (t), 28.4 (t), 24.1 (q), 7.1 (t). IR (neat) ν (cm-1) 2978, 2364. 
N-Methyl-N-(2-(1-(3-(2-methyl-1,3-dioxolan-2-yl)propyl)-1H-indol-3-yl)ethyl)formamide (43). 
Following the procedure used to prepare 27, ethyl (2-(1H-indol-3-yl)ethyl)carbamate25 (300 mg, 
1.29 mmol) was first treated with LiAlH4 (147 mg, 3.87 mmol) in THF (6.5 mL), then with water 
(0.1 mL), NaOH (15%, 0.1 mL), and water (0.3 mL) to afford a crude amino-alcohol that was used 
directly in the next step. Following the procedure used to prepare 19, crude amino-alcohol was treated 
with N-formylbenzotriazole (228 mg, 1.55 mmol) in THF (6.0 mL) and the usual work-up (DCM) and 
purification (60 to 100% EtOAc in hexanes then 2% MeOH in EtOAc) afforded N-(2-(1H-indol-3-
yl)ethyl)-N-methylformamide (42, 220 mg, 84% over 2 steps) as a white solid. Analytical data were in 
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accordance with those reported in the literature.26 1H NMR (300 MHz, CDCl3) 1:0.5 mixture of rotamers 
δ (ppm) 8.19 (br s, 1H), 8.06 (s) and 7.77 (s) (1H, rotamers), 7.65 (d, J = 8.0 Hz) and 7.56 (d, J = 8.0 Hz) 
(1H, rotamers), 7.37 (d, J = 8.0 Hz, 1H), 7.24-7.11 (m, 2H), 7.06 (s) and 6.96 (s) (1H, rotamers), 3.70-
3.65 (m) and 3.57-3.52 (m) (2H, rotamers), 3.06-2.99 (m, 2H), 2.94 (s) and 2.89 (s) (3H, rotamers). 
13C{1H} NMR mixture of rotamers (75 MHz, CDCl3) δ (ppm) 163.0 (d), 162.7 (d), 136.5 (s), 136.4 (s), 
127.4 (s), 126.9 (s), 122.7 (d), 122.1 (d), 122.0 (d), 119.5 (d), 119.3 (d), 118.6 (d), 118.2 (d), 111.6 (d), 
111.4 (d), 50.2 (t), 45.0 (t), 35.1 (q), 29.8 (q), 24.4 (t), 22.8 (t). IR (neat) ν (cm-1) 3287, 2918, 2855, 1653. 
HRMS (positive ESI) Calcd for C12H14N2ONa [MNa+]: 225.0998, found 225.0998. Mp 71 – 74 °C. A 
solution of 42 (218 mg, 1.08 mmol) in THF (0.54 mL) was added to a suspension of NaH (60% in min. 
oil, 86 mg, 2.16 mmol) in THF (2.2 mL). The reaction mixture was stirred for 15 min at rt then 41 
(276 mg, 1.08 mmol) was added. The resulting mixture was stirred for 3 h at rt then water was added. The 
usual work-up (DCM) and purification (70 to 100% EtOAc in hexanes then 2% MeOH in EtOAc) afforded 
43 (242 mg, 68%) as a yellow oil. 1H NMR (300 MHz, CDCl3) 1:0.5 mixture of rotamers δ (ppm) 8.06 
(s) and 7.83 (s) (1H, rotamers), 7.63 (d, J = 8.0 Hz) and 7.54 (d, J = 8.0 Hz) (1H, rotamers), 7.34 (d, J = 
3.5 Hz) and 7.31 (d, J = 3.5 Hz) (1H, rotamers), 7.24-7.18 (m, 1H), 7.14-7.08 (m, 1H), 6.97 (s) and 6.88 
(s) (1H, rotamers), 4.09 (t, J = 7.0 Hz, 2H), 3.97-3.86 (m, 4H), 3.67-3.62 (m) and 3.55-3.50 (m) (2H, 
rotamers), 3.03-2.97 (m, 2H), 2.93 (s) and 2.88 (s) (3H, rotamers), 1.92 (dt, J = 12.0, 7.5 Hz, 2H), 1.66 
(dd, J = 10.0, 6.0 Hz, 2H), 1.29 (s) and 1.28 (s) (3H, rotamers). 13C{1H} NMR mixture of rotamers 
(75 MHz, CDCl3) δ (ppm) 162.6 (d), 162.3 (d), 136.3 (s), 136.2 (s), 127.7 (s), 127.3 (s), 125.8 (d), 125.5 
(d), 121.6 (d), 121.4 (d), 118.8 (d), 118.7 (d), 118.3 (d), 111.1 (s), 110.1 (s), 109.6 (d), 109.5 (s), 109.3 
(d), 64.5 (t), 50.0 (t), 46.1 (t), 46.0 (t), 44.9 (t), 36.2 (t), 36.1 (t), 34.8 (q), 29.5 (q), 24.7 (t), 24.3 (t), 23.8 
(q), 22.6 (t). IR (neat) ν (cm-1) 2944, 2877, 1667, 1063. HRMS (positive ESI) Calcd for C19H26N2O3Na 
[MNa+]: 353.1836, found 353.1835. 
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N-(2-(1-Methyl-1H-indol-3-yl)ethyl)-N-(4-oxopentyl)formamide (44a). Trifluroroacetic acid 
(1.5 mL, 19.4 mmol) was added to a solution of tert-butyl (2-(1-methyl-1H-indol-3-yl)ethyl)carbamate 
(886 mg, 3.23 mmol) in DCM (16 mL) at 0 °C. The solution was stirred for 18 h at rt then a saturated 
aqueous solution of Na2CO3 (20 mL) was added. The usual workup (DCM) afforded the crude primary 
amine (338 mg, 1.94 mmol) that was used directly in the next step. Following the procedure used to 
prepare 24, crude primary amine was treated with AlMe3 (2.0 M in toluene, 0.97 mL, 1.94 mmol) and -
valerolactone (0.15 mL, 1.62 mmol) in DCM (13 mL). The usual workup (DCM) and purification (50 to 
100% EtOAc in hexanes then 1% MeOH in EtOAc) afforded 4-hydroxy-N-(2-(1-methyl-1H-indol-3-
yl)ethyl)pentanamide (405 mg, 91%) as an orange oil. 1H NMR (300 MHz, CDCl3) δ (ppm) 7.59 (d, J = 
8.0 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.23 (dd, J = 8.0, 1.0 Hz, 1H), 7.12 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 
6.90 (s, 1H), 5.66 (br s, 1H), 3.83-3.78 (m, 1H), 3.76 (s, 3H), 3.59 (dd, J = 13.0, 6.5 Hz, 2H), 2.96 (t, J = 
7.0 Hz, 2H), 2.80 (br s, 1H), 2.27 (dd, J = 10.5, 4.0 Hz, 2H), 1.83-1.58 (m, 2H), 1.17 (d, J = 6.2 Hz, 3H). 
13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 173.8 (s), 137.2 (s), 127.9 (s), 126.9 (d), 121.8 (d), 119.0 (d), 
118.9 (d), 111.5 (s), 109.4 (d), 67.4 (d), 40.1 (t), 34.4 (t), 33.3 (t), 32.7 (q), 25.2 (t), 23.6 (q). IR (neat) ν 
(cm-1) 3305 (br), 2922, 1639, 1549, 739. HRMS (positive ESI) Calcd for C16H22N2O2Na [MNa+]: 
297.1573, found 297.1579. Following the procedure used to prepare 27, 4-hydroxy-N-(2-(1-methyl-1H-
indol-3-yl)ethyl)pentanamide (405 mg, 1.48 mmol) was first treated with LiAlH4 (112 mg, 2.96 mmol) in 
THF (5.0 mL), then with water (0.11 mL), NaOH (15%, 0.11 mL), and water (0.33 mL) to afford a crude 
amino-alcohol that was used directly in the next step. Following the procedure used to prepare 19, crude 
amino-alcohol was treated with N-formylbenzotriazole (458 mg, 3.11 mmol) in THF (5 mL) to afford 
crude N,O-bisformylated product that was used directly in the next step. The residue then treated with 
K2CO3 (430 mg, 3.11 mmol) in MeOH (10 mL) and the usual work-up (EtOAc) and purification (40 to 
100% EtOAc in hexanes then 1 to 3% MeOH in EtOAc) afforded N-(4-hydroxypentyl)-N-(2-(1-methyl-
1H-indol-3-yl)ethyl)formamide (252 mg, 59% over 3 steps) as a yellow oil. 1H NMR (300 MHz, CDCl3) 
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1:0.8 mixture of rotamers δ (ppm) 8.09 (s) and 7.82 (s) (1H, rotamers), 7.64 (d, J = 8.0 Hz) and 7.53 (d, 
J = 8.0 Hz) (1H, rotamers), 7.31 (d, J = 3.5 Hz) and 7.29 (d, J = 3.5 Hz) (1H rotamers), 7.25-7.20 (m, 
1H), 7.15-7.09 (m, 1H), 6.91 (s) and 6.82 (s) (1H, rotamers), 3.89-3.79 (m, 1H), 3.74 (s, 3H), 3.63-3.58 
(m, 1H), 3.51 (t, J = 7.0 Hz, 1H), 3.49-3.31 (m, 1H), 3.18 (t, J = 7.1 Hz, 1H), 3.00 (dt, J = 11.0, 8.0 Hz, 
2H).1.84-1.31 (m, 5H), 1.19 (d, J = 6.0 Hz) and 1.16 (d, J = 6.0 Hz) (3H, rotamers). 13C{1H} NMR 
(75 MHz, CDCl3) mixture of rotamers δ (ppm) 163.1 (d), 162.9 (d), 137.2 (s), 137.0 (s), 127.8 (s), 127.4 
(s), 127.2 (d), 126.9 (d), 121.9 (d), 121.7 (d), 119.1 (d), 118.9 (d), 118.8 (d), 118.4 (d), 111.4 (s), 110.2 
(s), 109.5 (d), 109.3 (d), 67.5 (d), 67.4 (d), 48.1 (t), 48.0 (t), 43.4 (t), 42.3 (t), 36.1 (t), 35.8 (t), 32.8 (q), 
32.7 (q), 25.2 (t), 25.1 (t), 23.9 (t), 23.8 (q), 23.7 (q), 23.2 (t). IR (neat) ν (cm-1) 3390 (br), 2928, 1650, 
738. HRMS (positive ESI) Calcd for C17H24N2O2Na [MNa+]: 311.1730, found 311.1728. N-(4-
hydroxypentyl)-N-(2-(1-methyl-1H-indol-3-yl)ethyl)formamide (84 mg, 0.29 mmol) was then treated 
with Dess-Martin periodinane (246 mg, 0.58 mmol) in DCM (2.0 mL) and the usual workup (DCM) and 
purification (60 to 100% EtOAc in hexanes then 1% MeOH in EtOAc) afforded 44a (56 mg, 67%) as a 
yellow oil. 1H NMR (300 MHz, CDCl3) 1:0.7 mixture of rotamers δ (ppm) 8.05 (s) and 7.80 (s) (1H, 
rotamers), 7.65 (d, J = 8.0 Hz) and 7.54 (d, J = 8.0 Hz) (1H, rotamers), 7.31-7.20 (m, 2H), 7.12 (t, J = 7.0 
Hz, 1H), 6.91 (s) and 6.82 (s) (1H, rotamers), 3.73 (s, 3H), 3.62-3.57 (m, 1H), 3.50 (t, J = 7.0 Hz, 1H), 
3.37 (t, J = 7.0 Hz, 1H), 3.16 (t, J = 7.0 Hz, 1H), 3.03-2.95 (m, 2H), 2.46 (t, J = 7.0 Hz) and 2.36 (t, J = 
7.0 Hz) (2H, rotamers), 2.13 (s) and 2.10 (s) (3H, rotamers), 1.92-1.72 (m, 2H). 13C{1H} NMR (75 MHz, 
CDCl3) mixture of rotamers δ (ppm) 208.0 (s), 207.3 (s), 163.2 (d), 162.8 (d), 137.2 (s), 137.0 (s), 127.8 
(s), 127.4 (s), 127.2 (d), 126.8 (d), 121.9 (d), 121.7 (d), 119.1 (d), 119.0 (d), 118.9 (d), 118.4 (d), 111.3 
(s), 110.2 (s), 109.5 (d), 109.3 (d), 47.9 (t), 46.9 (t), 43.3 (t), 41.4 (t), 40.6 (t), 39.7 (t), 32.8 (q), 32.7 (q), 
30.1 (q), 30.0 (q), 25.0 (t), 23.2 (t), 22.4 (t), 21.4 (t). IR (neat) ν (cm-1) 2932, 1711, 1662, 740. HRMS 
(positive ESI) Calcd for C17H22N2O2Na [MNa+]: 309.1573, found 309.1579. 
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N-(2-(1-Methyl-1H-indol-3-yl)ethyl)-N-(5-oxohexyl)formamideformamide (44b). Following the 
procedure used to prepare 44a, tert-butyl (2-(1-methyl-1H-indol-3-yl)ethyl)carbamate (886 mg, 
3.23 mmol) was treated with trifluroroacetic acid (1.5 mL, 19.4 mmol) in DCM (16 mL) to afford the 
crude primary amine (218 mg, 1.25 mmol) that was used directly in the next step. Following the procedure 
used to prepare 24, crude primary amine was treated with AlMe3 (2.0 M in toluene, 0.63 mL, 1.25 mmol) 
and 23 (0.11 mL, 1.04 mmol) in DCM (8.3 mL). The usual workup (DCM) and purification (80 to 100% 
EtOAc in hexanes then 2% MeOH in EtOAc) afforded 5-hydroxy-N-(2-(1-methyl-1H-indol-3-
yl)ethyl)hexanamide (298 mg, 99%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ (ppm) 7.59 (d, J = 
8.0 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.23 (dd, J = 8.0, 1.0 Hz, 1H), 7.12 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 
6.89 (s, 1H), 5.57 (br s, 1H), 3.76 (s, 3H), 3.73-3.69 (m, 1H), 3.59 (dd, J = 12.5, 6.5 Hz, 2H), 2.96 (t, J = 
7.0 Hz, 2H), 2.14 (td, J = 7.0, 2.5 Hz, 2H), 1.84 (br s, 1H), 1.73-1.63 (m, 2H), 1.45-1.38 (m, 2H), 1.16 (d, 
J = 6.0 Hz, 3H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 173.2 (s), 137.2 (s), 127.9 (s), 126.9 (d), 121.9 
(d), 119.0 (d), 118.9 (d), 111.6 (s), 109.4 (d), 67.4 (d), 40.0 (t), 38.7 (t), 36.4 (t), 32.7 (q), 25.3 (t), 23.6 
(q), 21.7 (t). IR (neat) ν (cm-1) 3294 (br), 2928, 1641, 1550. HRMS (positive ESI) Calcd for 
C17H24N2O2Na [MNa+]: 311.1730, found 311.1735. Following the procedure used to prepare 27, 5-
hydroxy-N-(2-(1-methyl-1H-indol-3-yl)ethyl)hexanamide (332 mg, 1.15 mmol) was first treated with 
LiAlH4 (87 mg, 2.30 mmol) in THF (8.3 mL), then with water (0.09 mL), NaOH (15%, 0.09 mL), and 
water (0.27 mL) to afford a crude amino-alcohol that was used directly in the next step. Following the 
procedure used to prepare 19, crude amino-alcohol was treated with N-formylbenzotriazole (244 mg, 
1.66 mmol) in THF (2.6 mL) to afford crude N,O-bisformylated product that was used directly in the next 
step. The residue then treated with K2CO3 (229 mg, 1.66 mmol) in MeOH (2.6 mL) and the usual work-
up (EtOAc) and purification (60 to 100% EtOAc in hexanes then 3% MeOH in EtOAc) afforded N-(5-
hydroxyhexyl)-N-(2-(1-methyl-1H-indol-3-yl)ethyl)formamide (171 mg, 72% over 3 steps) as a yellow 
oil. 1H NMR (300 MHz, CDCl3) 1:0.9 mixture of rotamers δ (ppm) 8.09 (s) and 7.82 (s) (1H, rotamers), 
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7.64 (d, J = 8.0 Hz) and 7.53 (d, J = 8.0 Hz) (1H, rotamers), 7.32 (d, J = 3.5 Hz) and 7.29 (d, J = 3.5 Hz) 
(1H, rotamers), 7.23 (dd, J = 3.5, 1.0 Hz) and 7.21 (dd, J = 3.5, 1.0 Hz) (1H, rotamers), 7.15-7.09 (m, 
1H), 6.91 (s) and 6.83 (s) (1H, rotamers), 3.83-3.78 (m, 1H), 3.75 (s, 3H), 3.63-3.68 (m, 1H), 3.51 (t, J = 
7.0 Hz, 1H), 3.38 (t, J = 7.5 Hz, 1H), 3.16 (t, J = 7.0 Hz, 1H), 2.99 (dt, J = 10.0, 7.5 Hz, 2H), 1.65-1.26 
(m, 7H), 1.19 (d, J = 4.5 Hz) and 1.17 (d, J = 4.5 Hz) (3H, rotamers). 13C{1H} NMR (75 MHz, CDCl3) 
mixture of rotamers δ (ppm) 163.0 (d), 162.8 (d), 137.1 (s), 137.0 (s), 127.8 (s), 127.3 (s), 127.1 (d), 126.8 
(d), 121.8 (d), 121.6 (d), 119.0 (d), 118.9 (d), 118.8 (d), 118.3 (d), 111.3 (s), 110.2 (s), 109.5 (d), 109.2 
(d), 67.6 (d), 67.5 (d), 48.0 (t), 47.9 (t), 43.3 (t), 42.1 (t), 38.7 (t), 38.6 (t), 32.7 (q), 32.6 (q), 28.7 (t), 27.4 
(t), 25.0 (t), 23.6 (q), 23.5 (q), 23.2 (t), 23.0 (t), 22.7 (t). IR (neat) ν (cm-1) 3407 (br), 2930, 2861, 1652. 
HRMS (positive ESI) Calcd for C18H26N2O2Na [MNa+]: 325.1886, found 325.1890. Following the 
procedure to prepare 28c, N-(5-hydroxyhexyl)-N-(2-(1-methyl-1H-indol-3-yl)ethyl)formamide (86 mg, 
0.28 mmol) was treated with Dess-Martin periodinane (178 mg, 0.42 mmol) in DCM (5.6 mL) and the 
usual workup (DCM) and purification (40 to 100% EtOAc in hexanes) afforded 44b (53 mg, 63%) as a 
yellow oil. 1H NMR (300 MHz, CDCl3) 1:0.8 mixture of rotamers δ (ppm) 8.08 (s) and 7.81 (s) (1H, 
rotamers), 7.63 (d, J = 8.0 Hz) and 7.53 (d, J = 8.0 Hz) (1H, rotamers), 7.31 (d, J = 3.5 Hz) and 7.28 (d, 
J = 3.5 Hz) (1H, rotamers), 7.25-7.20 (m, 1H), 7.12 (ddd, J = 8.5, 3.0, 1.5 Hz, 1H), 6.91 (s) and 6.83 (s) 
(1H, rotamers), 3.74 (s, 3H), 3.60 (dd, J = 8.5, 7.0 Hz, 1H), 3.50 (t, J = 7.0 Hz, 1H), 3.37 (t, J = 7.0 Hz, 
1H), 3.14 (t, J = 6.5 Hz, 1H), 2.99 (m, 2H), 2.49-2.35 (m, 2H), 2.13 (s) and 2.11 (s) (3H, rotamers), 1.60-
1.46 (m, 4H). 13C{1H} NMR (75 MHz, CDCl3) mixture of rotamers δ (ppm) 208.7 (s), 208.1 (s), 163.0 
(d), 162.8 (d), 137.2 (s), 137.1 (s), 127.8 (s), 127.4 (s), 127.2 (d), 126.9 (d), 121.9 (d), 121.7 (d), 119.1 
(d), 119.0 (d), 118.8 (d), 118.4 (d), 111.4 (s), 110.2 (s), 109.6 (d), 109.3 (d), 48.0 (t), 47.9 (t), 43.4 (t), 
43.0 (t), 42.9 (t), 41.8 (t), 32.8 (q), 32.7 (q), 30.1 (q), 30.0 (q), 28.3 (t), 26.8 (t), 25.1 (t), 23.3 (t), 20.9 (t), 
20.6 (t). IR (neat) ν (cm-1) 2936, 2871, 1710, 1659. HRMS (positive ESI) Calcd for C18H24N2O2Na 
[MNa+]: 323.1730, found 323.1730. 
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N-Methyl-N-(2-(1-(4-oxopentyl)-1H-indol-3-yl)ethyl)formamide (44c). p-TsOH (42 mg, 
0.22 mmol) was added to a solution of 43 (242 mg, 0.73 mmol) in acetone/H2O (1:1, 4.0 mL). The 
solution was stirred for 18 h at rt then a saturated solution of NaHCO3 was added. The usual workup 
(Et2O) and purification (50 to 100% EtOAc in hexanes then 2% MeOH in EtOAc) afforded 44c (175 mg, 
84%) as a yellow oil. 1H NMR (300 MHz, CDCl3) 1:0.5 mixture of rotamers δ (ppm) 8.06 (s) and 7.74 
(s) (1H, rotamers), 7.63 (d, J = 8.0 Hz) and 7.54 (d, J = 8.0 Hz) (1H, rotamers), 7.33 (d, J = 4.0 Hz) and 
7.30 (d, J = 4.0 Hz) (1H, rotamers), 7.25-7.18 (m, 1H), 7.15-7.09 (m, 1H), 6.94 (s) and 6.83 (s) (1H, 
rotamers), 4.11 (t, J = 7.0 Hz, 2H), 3.68-3.63 (m) and 3.55-3.50 (m) (2H, rotamers), 3.03-2.97 (m, 2H), 
2.93 (s) and 2.91 (s) (3H, rotamers), 2.39-2.32 (m, 2H), 2.12-2.03 (m, 5H). 13C{1H} NMR mixture of 
rotamers (75 MHz, CDCl3) δ (ppm) 207.8 (s), 207.7 (s), 162.7 (d), 162.4 (d), 136.4 (s), 136.3 (s), 127.8 
(s), 127.3 (s), 126.0 (d), 125.5 (d), 121.9 (d), 121.7 (d), 119.1 (d), 118.9 (d), 118.8 (d), 118.5 (d), 111.5 
(s), 110.4 (s), 109.6 (d), 109.4 (d), 50.0 (t), 44.9 (t), 39.9 (t), 39.8 (t), 34.9 (q), 30.0 (q), 29.5 (q), 24.2 (t), 
24.1 (t), 24.0 (t), 22.6 (t). IR (neat) ν (cm-1) 2932, 1711, 1666. HRMS (positive ESI) Calcd for 
C17H22N2O2Na [MNa+]: 309.1573, found 309.1571. 
cis-1-(1,2,3,5,6,10b-Hexahydrodipyrrolo[1,2-a:2',1'-c]pyrazin-1-yl)ethan-1-one (49a). Following 
the procedure used to prepare 18a, 39a (67 mg, 0.30 mmol) was treated with triflic anhydride (56 µL, 
0.33 mmol) and DTBMP (68 mg, 0.33 mmol) in DCM (6.0 mL). 1H NMR analysis of a small sample of 
the reaction mixture revealed the presence of an iminium ion resulting from the Vilsmeier-Haack 
cyclization. 1H NMR (300 MHz, CDCl3) δ (ppm) 8.70 (s, 1H), 7.38 (s, 1H), 7.27 (s, 1H), 6.48 (dd, J = 
4.5, 2.5 Hz, 1H), 4.49-4.45 (m, 2H), 4.10 (t, J = 6.5 Hz, 2H), 3.91 (t, J = 7.0 Hz, 2H), 2.68-2.63 (m, 2H), 
2.12 (s, 3H), 2.11-2.01 (m, 2H). Subsequent treatment with pyrrolidine (75 µL, 0.90 mmol) added at 0 °C 
then stirred at rt for 18 h followed by the usual work-up (DCM) and purification (5 to 80% EtOAc in 
hexanes with 1.5% Et3N) afforded 49a (53 mg, 87%) as a yellow solid. 1H NMR (300 MHz, CDCl3) δ 
(ppm) 6.57-6.55 (m, 1H), 6.14-6.12 (m, 1H), 5.81-5.80 (m, 1H), 4.09-4.01 (m, 2H), 3.92 (dt, J = 12.0, 4.0 
 54 
Hz, 1H), 3.22-3.13 (m, 2H), 3.08-2.93 (m, 2H), 2.87-2.79 (m, 1H), 2.29 (s, 3H), 2.08-1.92 (m, 2H). 
13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 209.2 (s), 129.8 (s), 119.1 (d), 108.1 (d), 103.3 (d), 61.2 (d), 
56.8 (d), 51.9 (t), 47.5 (t), 43.0 (t), 30.0 (q), 28.1 (t). IR (neat) ν (cm-1) 2921, 1706, 720. HRMS (positive 
ESI) Calcd for C12H17N2O [M + H+]: 205.1335, found 205.1340. 
cis-1-(5,6,9,10,11,11a-Hexahydro-8H-pyrido[1,2-a]pyrrolo[2,1-c]pyrazin-11-yl)ethan-1-one 
(49b). Following the procedure used to prepare 18a, 39b (14 mg, 0.06 mmol) was treated with triflic 
anhydride (12 µL, 0.07 mmol) and DTBMP (14 mg, 0.07 mmol) in CDCl3 (1.2 mL). 1H NMR analysis of 
a small sample of the reaction mixture revealed the presence of an iminium ion resulting from the 
Vilsmeier-Haack cyclization. 1H NMR (300 MHz, CDCl3) δ (ppm) 8.72 (s, 1H), 7.37 (s, 1H), 7.28 (s, 
1H), 6.48 (dd, J = 4.0, 2.5 Hz, 1H), 4.47 (t, J = 6.5 Hz, 2H), 4.09 (t, J = 6.5 Hz, 2H), 3.92 (t, J = 7.0 Hz, 
2H), 2.55 (t, J = 6.5 Hz, 2H), 2.12 (s, 3H), 1.87-1.77 (m, 2H), 1.67-1.61 (m, 2H). Subsequent treatment 
with pyrrolidine (30 µL, 0.36 mmol) added at 0 °C then stirred at rt for 3 h followed by the usual work-
up (DCM) and purification (2 to 50% EtOAc in hexanes with 1.5% Et3N) afforded 49b (53 mg, 87%) as 
a yellow solid. 1H NMR (300 MHz, CDCl3) δ (ppm) 6.52-6.47 (m, 1H), 6.07-6.05 (m, 1H), 5.57 (d, J = 
3.5 Hz, 1H), 4.09 (td, J = 12.0, 5.0 Hz, 1H), 3.90 (dd, J = 11.0, 3.5 Hz, 1H), 3.62 (d, J = 10.0 Hz, 1H), 
3.02-2.75 (m, 4H), 2.42-2.37 (m, 1H), 2.32 (s, 3H), 2.00-1.95 (m, 1H), 1.77-1.63 (m, 2H), 1.50-1.36 (m, 
1H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 211.6 (s), 129.4 (s), 119.0 (d), 108.2 (d), 103.8 (d), 60.9 
(d), 55.0 (t), 54.6 (d), 52.7 (t), 44.8 (t), 30.3 (q), 28.8 (t), 24.7 (t). IR (neat) ν (cm-1) 2923, 2790, 1705. 
HRMS (positive ESI) Calcd for C13H19N2O [M + H+]: 219.1492, found 219.1503. Mp 104 – 107 °C.  
cis-1-(11-Methyl-2,3,5,6,11,11b-hexahydro-1H-indolizino[8,7-b]indol-1-yl)ethan-1-one (50a). 
Following the procedure used to prepare 18a, 44a (52 mg, 0.18 mmol) was treated with triflic anhydride 
(34 µL, 0.20 mmol) and DTBMP (41 mg, 0.20 mmol) in DCM (3.6 mL). Subsequent treatment with 
pyrrolidine (45 µL, 0.54 mmol) added at 0 °C then stirred at rt for 18 h followed by the usual work-up 
(DCM) and purification (5 to 70% EtOAc in hexanes with 1.5% Et3N) afforded 50a (9.0 mg, 19%) as a 
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yellow oil. 1H NMR (300 MHz, CDCl3) δ (ppm) 7.49 (d, J = 8.0 Hz, 1H), 7.24-7.07 (m, 3H), 4.94 (d, J 
= 5.0 Hz, 1H), 3.50 (s, 3H), 3.29-2.89 (m, 6H), 2.71-2.62 (m, 1H), 2.31 (s, 3H), 2.08-1.98 (m, 2H). 
13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 208.6 (s), 137.5 (s), 135.9 (s), 126.8 (s), 121.5 (d), 119.3 (d), 
118.3 (d), 108.9 (d), 107.5 (s), 57.3 (d), 56.6 (d), 50.2 (t), 46.0 (t), 30.5 (q), 29.9 (t), 28.9 (q), 17.5 (t). IR 
(neat) ν (cm-1) 2921, 1707, 748. HRMS (positive ESI) Calcd for C17H21N2O [M + H+]: 269.1648, found 
269.1652.  
1-(12-Methyl-1,2,3,4,6,7,12,12b-octahydroindolo[2,3-a]quinolizin-1-yl)ethan-1-one (50b). 
Following the procedure used to prepare 18a, 44b (99 mg, 0.33 mmol) was treated with triflic anhydride 
(61 µL, 0.36 mmol) and DTBMP (74 mg, 0.36 mmol) in CHCl3 (6.6 mL). Subsequent treatment with 
pyrrolidine (0.17 mL, 1.98 mmol) added at 0 °C then stirred at 0 °C for 2 h then at rt for 18 h followed by 
concentration under reduce pressure and the usual purification (2 to 80% EtOAc in hexanes with 1.5% 
Et3N) afforded cis-50b (22 mg) and trans-50b (20 mg) (49%) as yellow oils. cis-50b: 1H NMR 
(300 MHz, CDCl3) δ (ppm) 7.50 (d, J = 8.0 Hz, 1H), 7.23-7.17 (m, 2H), 7.13-7.07 (m, 1H), 4.12 (d, J = 
10.0 Hz, 1H), 3.63-3.52 (m, 1H), 3.39 (s, 3H), 3.31-3.21 (m, 3H), 3.00-2.89 (m, 3H), 2.04-1.86 (m, 3H), 
1.83 (s, 3H), 1.46-1.39 (m, 1H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 212.6 (s), 138.5 (s), 136.3 (s), 
127.5 (s), 121.8 (d), 119.4 (d), 118.4 (d), 109.7 (d), 108.2 (s), 56.5 (d), 54.5 (t), 49.6 (d), 43.9 (t), 32.4 (q), 
30.9 (q), 27.8 (t), 21.6 (t), 18.3 (t). IR (neat) ν (cm-1) 2933, 2857, 1701, 1467, 737. HRMS (positive ESI) 
Calcd for C18H23N2O [M + H+]: 283.1805, found 283.1802. Rf = 0.49, 70% EtOAc/Hexanes with Et3N). 
trans-50b: 1H NMR (300 MHz, CDCl3) δ (ppm) 7.50 (d, J = 8.0 Hz, 1H), 7.30 (d, J = 8.0 Hz, 1H), 7.21 
(t, J = 7.0 Hz, 1H), 7.14-7.10 (m, 1H), 3.79 (d, J = 2.0 Hz, 1H), 3.75 (s, 3H), 3.18-3.16 (m, 1H), 3.12-
2.89 (m, 3H), 2.76-2.69 (m, 1H), 2.63-2.51 (m, 2H), 2.41-2.37 (m, 1H), 2.18-2.00 (m, 1H), 1.70 (s, 3H), 
1.67-1.55 (m, 2H). 13C{1H} NMR (75 MHz, CDCl3) δ (ppm) 209.7 (s), 138.2 (s), 134.9 (s), 126.6 (s), 
121.6 (d), 119.5 (d), 118.3 (d), 110.8 (s), 109.1 (d), 62.2 (d), 57.3 (t), 53.4 (t), 51.1 (d), 31.7 (q), 30.2 (q), 
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27.5 (t), 22.3 (t), 22.0 (t). IR (neat) ν (cm-1) 2942, 2918, 1699, 1468, 736. Rf = 0.82, 70% EtOAc/Hexanes 
with Et3N). HRMS (positive ESI) Calcd for C18H23N2O [M + H+]: 283.1805, found 283.1808. 
cis-1-(3-Methyl-2,3,3a,4,5,6-hexahydro-1H-indolo[3,2,1-de][1,5]naphthyridin-4-yl)ethan-1-one 
(50c). Following the procedure used to prepare 18a, 44c (66 mg, 0.23 mmol) was treated with triflic 
anhydride (42 µL, 0.25 mmol) and DTBMP (51 mg, 0.25 mmol) in DCM (4.6 mL). Subsequent treatment 
with DIPEA (80 µL, 0.46 mmol) and L-prolinamide (6.0 mg, 0.05 mmol) added at 0 °C then stirred at rt 
for 18 h followed by the usual work-up (DCM) and purification (5 to 70% EtOAc in hexanes with 1.5% 
Et3N) afforded 50c (30 mg, 48%) as a yellow oil. 1H NMR (300 MHz, CDCl3) δ (ppm) 7.50 (d, J = 7.5 
Hz, 1H), 7.28 (m, 1H), 7.20-7.09 (m, 2H), 4.32-4.23 (m, 1H), 4.21 (d, J = 11.0 Hz, 1H), 3.76-3.66 (m, 
1H), 3.24-2.67 (m, 6H), 2.39 (s, 3H), 2.29 (s, 3H), 2.26-2.17 (m, 1H). 13C{1H} NMR (75 MHz, CDCl3) 
δ (ppm) 209.8, 137.1, 132.7, 128.0, 121.2, 119.8, 118.5, 109.4, 106.3, 59.8, 53.7, 50.1, 41.8, 38.6, 29.6, 
27.2, 18.8. IR (neat) ν (cm-1) 2956, 1732, 1402. HRMS (positive ESI) Calcd for C17H21N2O [M + H+]: 
269.1648, found 269.1660.  
 
Supporting Information Available. Copies 1H and 13C NMR spectra for all new compounds. This 







The manuscript was written through contributions of all authors. All authors have given approval to the 




The authors declare no competing financial interest. 
 
Acknowledgments. The authors want to thank Dr Daniel Fortin (U. Sherbrooke) for X-ray diffraction 
analyses. This research was supported by the Natural Science and Engineering Research Council 
(NSERC) of Canada and the Université de Sherbrooke.  
  
 58 
References and Footnotes 
1 For the biological activity of oleracein E, see: (a) Sun, H.; He, X.; Liu, C.; Li, L.; Zhou, R.; Jin, 
T.; Yue, S.; Feng, D.; Gong, J.; Sun, J.; Ji, J.; Xiang, L. Effect of Oleracein E, a Neuroprotective 
Tetrahydroisoquinoline, on Rotenone-Induced Parkinson’s Disease Cell and Animal Models. Chem. 
Neurosci. 2017, 8, 155-164. For the biological activity of harmicine, see: (b) Lood, C. S.; Koskinen; A. 
M. P. Harmicine, a Tetracyclic Tetrahydro--carboline: from the First Synthetic Precedent to Isolation 
from Natural Sources to Target-Oriented Synthesis. Chem. Heterocycl. Comp. 2015, 50, 1367-1387. For 
the biological activity of (–)-tangutorine, see: (c) Liu, B. P. L.; Chong, E. Y. Y.; Cheung, F. W. K.; Duan, 
J.-A.; Che, C.-T., Liu, W. K. Tangutorine Induces P21 Expression and Abnormal Mitosis in Human Colon 
Cancer HT-29 Cells. Biochem. Pharmacol. 2005, 70, 287-299. For the biological activity of vincamine, 
see: (d) Fayed, A.-H. A. Brain Trace Element Concentration of Rats Treated with the Plant Alkaloid, 
Vincamine. Biol. Trace Elem. Res. 2010, 136, 314-319. 
2 Bélanger, G.; O’Brien, G.; Larouche-Gauthier, R. Rapid Assembly of Quinolizidines via 
Consecutive Nucleophilic Cyclizations. Org. Lett. 2011, 13, 4268-4271. 
3 (a) Zou, W.; Sandbhor, M.; Bhasin, M. Stereoselective Synthesis of Polyhydroxylated 
Quinolizidines from C-Glycosides by One-Pot Double-Conjugate Addition. J. Org. Chem. 2007, 72, 
1226-1234; (b) Airiau, E.; Spangenberg, T.; Girard, N.; Breit, B.; Mann, A. Short Access to (+)-Lupinine 
and (+)-Epiquinamide via Double Hydroformylation. Org. Lett. 2010, 12, 528-531; (c) García, D.; 
Foubelo, F.; Yus, M. Reductive Ring‐Opening of Phthalan and Isochroman: Application to the 
Stereoselective Synthesis of Tetrahydroisoquinolines and Tetrahydrobenzazepines. Eur. J. Org. Chem. 
2010, 2893-2903; (d) Quinet, C.; Sampoux, L.; Markó, I. E. Base‐Catalysed Intramolecular 
Hydroamination of Vinyl Sulfides. Eur. J. Org. Chem. 2009, 1806-1811; (e) Amos, D. T.; Renslo, A. R.; 





Azadienophiles for Hetero Diels−Alder Reactions. J. Am. Chem. Soc. 2003, 125, 4970-4971; (f) Fang, 
H.; Wu, X.; Nie, L.; Dai, X.; Chen, J.; Cao, W.; Zhao, G. Diastereoselective Syntheses of 
Indoloquinolizidines by a Pictet−Spengler/Lactamization Cascade Org. Lett. 2010, 12, 5366-5369. 
4 For a selection of recent examples of cyclizations involving a Mannich reaction, see ref. 2 and: (a) 
Kim, K.; Kim, H. Y.; Oh, K. Aerobic Oxidation Approaches to Indole-3-carboxylates: A Tandem Cross 
Coupling of Amines-Intramolecular Mannich-Oxidation Sequence. Org. Lett. 2019, 21, 6731-6735; (b) 
Ju, X.; Beaudry, C. M. Total Synthesis of (-)-Cephalotaxine and (-)-Homoharringtonine via Furan 
Oxidation-Transannular Mannich Cyclization. Angew. Chem. Int. Ed. 2019, 58, 6752-6755; (c) Gan, P.; 
Pitzen, J.; Qu, P.; Snyder, S. A. Total Synthesis of the Caged Indole Alkaloid Arboridinine Enabled by 
aza-Prins and Metal-Mediated Cyclizations. J. Am. Chem. Soc. 2018, 140, 919-925; (d) Srinivas, K.; 
Singh, N.; Das, D.; Koley, D. Organocatalytic, Asymmetric Synthesis of Aza-Quaternary Center of 
Izidine Alkaloids: Synthesis of (-)-Tricyclic Skeleton of Cylindricine. Org. Lett. 2017, 19, 274-277. 
5 For reviews on organocatalyzed asymmetric Mannich reactions, see: (a) Verkade, J. M. M.; van 
Hemert, L. J. C.; Quaedflieg, P. J. L. M.; Rutjes, F. P. J. T. Organocatalysed Asymmetric Mannich 
Reactions. Chem. Soc. Rev. 2008, 37, 29-41; (b) Evans, C. S.; Davis, L. O. Recent Advances in 
Organocatalyzed Domino C-C Bond-forming Reactions. Molecules 2018, 23, 33. For a selection of recent 
examples of organocatalyzed Mannich reaction, see: (c) Rostoll-Berenguer, J.; Blay, G.; Munoz, M. C.; 
Pedro, J. R.; Vila, C. A Combination of Visible-Light Organophotoredox Catalysis and Asymmetric 
Organocatalysis for the Enantioselective Mannich Reaction of Dihydroquinoxalinones with Ketones. Org. 
Lett. 2019, 21, 6011-6015; (d) Mukhopadhyay, S.; Pan, S. C. Organocatalytic Asymmetric Mannich 
Reaction of Dihydro-3-carboalkoxy-2-quinolones with Preformed N-Boc Imines. Eur. J. Org. Chem. 
2019, 2639-2642; (e) Zhang, J.; Zhao, G. Enantioselective Mannich reaction of γ-Malonate-substituted 
α,β-Unsaturated Esters with N-Boc Imines Catalyzed by Chiral Bifunctional Thiourea-phosphonium 




Asymmetric Mannich Reaction for the Synthesis of 3,3-Disubstituted-3,4-dihydro-2-quinolones. Org. 
Biomol. Chem. 2018, 16, 5407-5411. 
6 One-pot amide activation and nucleophilic trapping in the presence of a ketone has been reported 
for the first time by our group and the group of Charette. See: (a) Lévesque, F.; Bélanger, G. A Versatile 
Cascade of Intramolecular Vilsmeier-Haack and Azomethine Ylide 1,3-Dipolar Cycloaddition toward 
Tricyclic Cores of Alkaloids. Org. Lett. 2008, 10, 4939-4942; (b) Barbe, G.; Charette, A. B. Highly 
Chemoselective Metal-Free Reduction of Tertiary Amides. J. Am. Chem. Soc. 2008, 130, 18-19. Related 
amide transformation to thioamide in the presence of a ketone and subsequent reduction of the thioamide 
has already been reported. For example, see: Maloney, D. J.; Danishefsky, S. J. Conformational Locking 
through Allylic Strain as a Device for Stereocontrol – Total Synthesis of Grandisine A. Angew. Chem. 
Int. Ed. 2007, 46, 7789-7792. 
7 Lampe, T. F. J.; Hoffmann, H. M. R. Asymmetric Synthesis of the C(10)-C(16) Segment of 
Bryostatins. Tetrahedron Lett. 1996, 37, 7695-7698. 
8 Marshall, J. A.; Shearer, B. G.; Crooks, S. L. Thermal and Catalyzed Intramolecular Diels-Alder 
Cyclizations of 2,8,10-Undecatrienals. J. Org. Chem. 1987, 52, 1236-1245. 
9 Other solvents, such as DCM and 1,2-dichloroethane, were tested without significant change in 
the results. Solvents that were not compatible with the amide activation conditions were also tested, such 
as DMSO and DMF. In those cases, we had to evaporate chloroform after amide activation and Vilsmeier-
Haack cyclization, then dilute with the chosen solvent. Although we proved that concentration and 
dilution did not affect the iminium ion intermediate (dilution with chloroform gave essentially the same 
results as entry 5), lower yields were obtained. 
10 The use of additives such as TBAC or pyridine N-oxide, known to favor the formation of the 




J.; Lu, Z.; Flach A. L.; Paton, R. S.; Hammond, G. B.; Xu, B. Role of Hydrogen‐Bonding Acceptors in 
Organo‐Enamine Catalysis. Chem. Eur. J. 2015, 21, 11687-11691. 
11 Addition of a first equivalent of secondary amine just deprotonated DTBMPH+. After a second 
equivalent of secondary amine added, we could not see any basic amine yet; we presumed that two 
secondary amines were forming a stable monoptotonated dimeric complex in CDCl3. 
12 CCDC 1971902 (for compound 18a), 1971904 (for compound 30a), 1971903 (for compound 
30b), 1971905 (for compound 30f), and 1971901 (for compound 51b) contain the supplementary 
crystallographic data for this paper. These data can be obtained free of charge via 
www.ccdc.cam.ac.uk/data_request/cif. 
13 For representation of X-ray structure: CYLview, 1.0b; Legault, C. Y., Université de Sherbrooke, 
2009 (http://www.cylview.org). 
14 Galeazzi, E.; Guzman, A.; Pinedo, A.; Saldana, A.; Torre, D.; Muchowski, J. M. Synthesis of Ethyl 
1,2-Dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate by an Intramolecular Carbenoid Reaction. Can. J. 
Chem. 1983, 61, 454-456. 
15 Ameer, F.; Giles, R. G. F.; Green, I. R.; Nagabhushana, K. S. The DDQ Mediated Cyclization 
Products of Some 2-Hydroxy-3-(1′-alkenyl)-1,4-naphthoquinones. Synth. Comm. 2002, 32, 369-380. 
16 Mahale, S.; Bharate, S. B.; Manda, S.; Joshi, P.; Bharate, S. S.; Jenkins, P. R.; Vishwakarma, R. 
A.; Chaudhuri, B. Biphenyl-4-carboxylic Acid [2-(1H-Indol-3-yl)-ethyl]-methylamide (CA224), a 
Nonplanar Analogue of Fascaplysin, Inhibits Cdk4 and Tubulin Polymerization: Evaluation of in Vitro 
and in Vivo Anticancer Activity. J. Med. Chem. 2014, 57, 9658-9672. 
17 (a) Ben-Ishai, D. Intramolecular Amidoalkylation of Olefins. J. Chem. Soc., Chem. Commun. 




Synthesis of 1-Azabicyclo[3.3.0]octane and 1-Azabicyclo[4.3.0]nonane Derivatives. J. Chem. Soc., 
Perkin Trans. 1 1984, 2477-2489. 
18 Other cyclization modes were tested in previous studies with different nucleophiles. In the present 
case, the aryl/heteroaryl nucleophile in the Vilsmeier-Haack limits the cyclization to 5-endo and 6-endo 
modes with respect to the nucleophile, the former being much less efficient. See: (a) Bélanger, G.; 
Larouche-Gauthier, R.; Ménard, F.; Nantel, M.; Barabé, F. Addition of Tethered Nonaromatic Carbon 
Nucleophiles to Chemoselectively Activated Amides. Org. Lett. 2005, 7, 4431-4434; (b) Bélanger, G.; 
Larouche-Gauthier, R.; Ménard, F.; Nantel, M.; Barabé, F. Intramolecular Additions of Various -
Nucleophiles to Chemoselectively Activated Amides and Application to the Synthesis of (±)-
Tashiromine. J. Org. Chem. 2006, 71, 704-712. 
19 Anderson, A. G.; Stang, P. J. 2,6-Di-tert-butyl-4-methylpyridine. Org. Synth. 1981, 60, 34. 
20 Marshall, A.; Shearer, B. G.; Grooks, S. L. Thermal and Catalyzed Intramolecular Diels-AIder 
Cyclizations of 2,8,10-Undecatrienals. J. Org. Chem. 1987, 52, 1236−1245. 
21 Vohra, R.; Maclean, D. B. Enamines from fromamides. Synthesis of 1,2,3,4-tetrahydro-1-
substituted--carbolides. Can. J. Chem. 1994, 72, 1660-1667.  
22 Mecerreyes, D.; Pomposo, J. A.; Bengoetxea, M.; Grande, H. Novel Pyrrole End-Functional 
Macromonomers Prepared by Ring-Opening and Atom-Transfer Radical Polymerizations. 
Macromolecules 2000, 33, 5846-5849. 
23 Galeazzi, E.; Guzman, A.; Pinedo, A.; Saldana, A.; Torre, D.; Muchowski, J. M. Synthesis of 
Ethyl 1,2-Dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylate by an Intramolecular Carbenoid Reaction. 




24 Wu, Y.; Ahlberg, P. A Convenient Procedure for Preparing 2-(3-Iodopropyl)-2-methyl-1,3-
dioxolane. Synthesis 1994, 463-464. 
25 Mahale, S.; Bharate, S. B.; Manda, S.; Joshi, P.; Bharate, S. S.; Jenkins, P. R.; Vishwakarma, R. 
A.; Chaudhuri, B. Biphenyl-4-carboxylic Acid [2-(1H-Indol-3-yl)-ethyl]-methylamide (CA224), a 
Nonplanar Analogue of Fascaplysin, Inhibits Cdk4 and Tubulin Polymerization: Evaluation of in Vitro 
and in Vivo Anticancer Activity. J. Med. Chem. 2014, 57, 9658-9672. 
26 Lindel, T.; Bra1uchle, L.; Golz, G.; Bo1hrer, P. Total Synthesis of Flustramine C via 
Dimethylallyl Rearrangement. Org. Lett. 2007, 9, 283-286. 
